CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | 3',5'-cyclic AMP |
|
Accession: | CHEBI:17489
|
browse the term
|
Definition: | A 3',5'-cyclic purine nucleotide having having adenine as the nucleobase. |
Synonyms: | exact_synonym: | adenosine 3',5'-(hydrogen phosphate) |
| related_synonym: | Adenosine 3',5'-cyclic phosphate; Adenosine 3',5'-phosphate; Cyclic AMP; Cyclic adenylic acid; Formula=C10H12N5O6P; InChI=1S/C10H12N5O6P/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(16)7-4(20-10)1-19-22(17,18)21-7/h2-4,6-7,10,16H,1H2,(H,17,18)(H2,11,12,13)/t4-,6-,7-,10-/m1/s1; InChIKey=IVOMOUWHDPKRLL-KQYNXXCUSA-N; SMILES=Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1O; adenosine 3',5'-cyclic monophosphate; cAMP |
| alt_id: | CHEBI:11673; CHEBI:1325; CHEBI:19827; CHEBI:41588 |
| xref: | Beilstein:52645; CAS:60-92-4; DrugBank:DB02527; HMDB:HMDB0000058; KEGG:C00575; KNApSAcK:C00001497 |
| xref_mesh: | MESH:D000242 |
| xref: | MetaCyc:CAMP; PDBeChem:CMP; PMID:16295522; PMID:18372334; PMID:22770225; Reaxys:52645; Wikipedia:Cyclic_AMP |
| cyclic_relationship: | is_conjugate_acid_of CHEBI:58165 |
|
|
|
G |
Abca1 |
ATP-binding cassette, sub-family A member 1 |
increases expression multiple interactions |
EXP |
Cyclic AMP results in increased expression of ABCA1 mRNA; Cyclic AMP results in increased expression of ABCA1 protein [HCAR2 protein results in decreased abundance of Cyclic AMP] which results in decreased expression of ABCA1 protein |
CTD |
PMID:20339114 PMID:20655299 |
|
NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895
|
|
G |
Abcc4 |
ATP-binding cassette, sub-family C member 4 |
increases transport multiple interactions affects uptake |
ISO EXP |
ABCC4 protein results in increased transport of Cyclic AMP Probenecid affects the reaction [ABCC4 protein affects the uptake of Cyclic AMP analog] |
CTD |
PMID:11856762 PMID:28587784 |
|
NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
multiple interactions |
ISO |
[ADCYAP1 protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:7733904 |
|
NCBI chr17:93,506,448...93,513,967
Ensembl chr17:93,506,445...93,513,965
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases abundance |
ISO |
ADIPOQ protein results in increased abundance of Cyclic AMP |
CTD |
PMID:18931039 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Adm |
adrenomedullin |
multiple interactions increases abundance |
ISO |
ADM protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]; CALCA protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]; Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP] ADM protein results in increased abundance of Cyclic AMP; ADM results in increased abundance of Cyclic AMP |
CTD |
PMID:10374718 PMID:17306419 |
|
NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027
|
|
G |
Adra1b |
adrenergic receptor, alpha 1b |
multiple interactions |
EXP |
ADRA1B protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP] |
CTD |
PMID:12649302 |
|
NCBI chr11:43,665,432...43,792,076
Ensembl chr11:43,665,433...43,792,037
|
|
G |
Adrb1 |
adrenergic receptor, beta 1 |
multiple interactions increases abundance affects abundance |
ISO |
[3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Bupranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Epinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; ADRB1 protein polymorphism affects the reaction [[carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP]; Alprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bisoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bupranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; carvedilol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; Isoproterenol promotes the reaction [ADRB1 protein results in increased abundance of Cyclic AMP]; Metoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Nadolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Oxprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Pindolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Sotalol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Timolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP] ADRB1 protein affects the abundance of Cyclic AMP; ADRB1 protein polymorphism affects the abundance of Cyclic AMP ADRB1 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP] |
CTD |
PMID:11562432 PMID:12761341 PMID:14502278 PMID:14730417 PMID:15060759 PMID:17200720 PMID:18378355 PMID:18787115 PMID:19419905 More...
|
|
NCBI chr19:56,710,549...56,713,582
Ensembl chr19:56,710,631...56,721,545
|
|
G |
Adrb2 |
adrenergic receptor, beta 2 |
multiple interactions increases chemical synthesis increases abundance affects abundance |
ISO |
[Terbutaline results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; ADRB2 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP] ADRB2 protein polymorphism results in increased chemical synthesis of Cyclic AMP; ADRB2 protein results in increased chemical synthesis of Cyclic AMP [Acebutolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Betaxolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [BRL 37344 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [broxaterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [carvedilol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [carvedilol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Isoproterenol results in increased activity of ADRB2 protein] which results in increased chemical synthesis of Cyclic AMP; [Labetalol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Metaproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Metoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Nadolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Oxprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Practolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Propranolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Sotalol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Timolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; Atenolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP] ADRB2 protein results in increased abundance of Cyclic AMP ADRB2 protein affects the abundance of Cyclic AMP |
CTD |
PMID:10516654 PMID:10857765 PMID:10952688 PMID:11562432 PMID:12920204 PMID:14730417 PMID:16036225 PMID:16980553 PMID:17925438 PMID:18378355 PMID:19419905 PMID:21868359 PMID:27825928 More...
|
|
NCBI chr18:62,310,784...62,313,052
Ensembl chr18:62,310,887...62,313,030
|
|
G |
Adrb3 |
adrenergic receptor, beta 3 |
multiple interactions affects abundance |
ISO |
3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [[SR 59119A binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP]; [Albuterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [BRL 37344 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [broxaterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [Epinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [SR 59119A binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Terbutaline binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP ADRB3 protein affects the abundance of Cyclic AMP |
CTD |
PMID:10952688 PMID:14730417 |
|
NCBI chr 8:27,715,804...27,720,833
Ensembl chr 8:27,715,804...27,740,644
|
|
G |
Ahcyl1 |
S-adenosylhomocysteine hydrolase-like 1 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of AHCYL1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:107,570,436...107,603,876
Ensembl chr 3:107,570,434...107,603,876
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
multiple interactions decreases expression |
ISO |
AHR protein promotes the reaction [Cyclic AMP results in increased expression of CYP1B1 mRNA]; Cyclic AMP inhibits the reaction [AHR protein binds to ARNT protein]; Cyclic AMP promotes the reaction [AHR protein binds to CYP1B1 enhancer] 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA Cyclic AMP results in decreased expression of AHR protein |
CTD |
PMID:12859982 PMID:32781018 |
|
NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037
|
|
G |
Angptl4 |
angiopoietin-like 4 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ANGPTL4 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr17:33,993,874...34,000,549
Ensembl chr17:33,992,724...34,000,804
|
|
G |
Ank2 |
ankyrin 2, brain |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ANK2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:126,715,256...127,293,996
Ensembl chr 3:126,715,261...127,292,999
|
|
G |
Aqp3 |
aquaporin 3 |
multiple interactions increases expression |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA]; N-(2-aminoethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA] |
CTD |
PMID:12542607 |
|
NCBI chr 4:41,092,724...41,098,183
Ensembl chr 4:41,092,722...41,098,183
|
|
G |
Aqp5 |
aquaporin 5 |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [Cyclic AMP results in decreased expression of AQP5 protein]; Cyclic AMP affects the expression of and results in increased phosphorylation of and results in increased localization of AQP5 protein |
CTD |
PMID:15536076 |
|
NCBI chr15:99,488,909...99,492,710
Ensembl chr15:99,488,663...99,492,710
|
|
G |
Armh4 |
armadillo-like helical domain containing 4 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ARMH4 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr14:49,919,017...50,020,843
Ensembl chr14:49,913,409...50,020,840
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
Cyclic AMP inhibits the reaction [AHR protein binds to ARNT protein] |
CTD |
PMID:12859982 |
|
NCBI chr 3:95,341,674...95,404,551
Ensembl chr 3:95,341,699...95,404,551
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein |
CTD |
PMID:25191754 |
|
NCBI chr11:70,323,051...70,331,654
Ensembl chr11:70,323,461...70,331,654
|
|
G |
Atf5 |
activating transcription factor 5 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ATF5 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 7:44,461,680...44,466,082
Ensembl chr 7:44,461,680...44,466,082
|
|
G |
Avp |
arginine vasopressin |
multiple interactions |
ISO |
[AVP protein binds to and results in increased activity of AVPR2 protein mutant form] which results in increased abundance of Cyclic AMP; [AVP protein binds to and results in increased activity of AVPR2 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:20683494 |
|
NCBI chr 2:130,422,540...130,424,508
Ensembl chr 2:130,422,540...130,424,474
|
|
G |
Avpr2 |
arginine vasopressin receptor 2 |
multiple interactions increases abundance |
ISO |
[AVP protein binds to and results in increased activity of AVPR2 protein mutant form] which results in increased abundance of Cyclic AMP; [AVP protein binds to and results in increased activity of AVPR2 protein] which results in increased abundance of Cyclic AMP AVPR2 protein results in increased abundance of Cyclic AMP |
CTD |
PMID:20683494 PMID:33638691 |
|
NCBI chr X:72,935,371...72,938,034
Ensembl chr X:72,935,708...72,939,108
|
|
G |
Bdnf |
brain derived neurotrophic factor |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein |
CTD |
PMID:33713149 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Braf |
Braf transforming gene |
increases activity multiple interactions |
ISO |
Cyclic AMP results in increased activity of BRAF protein [Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein; [Theophylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein |
CTD |
PMID:21693435 |
|
NCBI chr 6:39,580,171...39,702,592
Ensembl chr 6:39,580,171...39,702,397
|
|
G |
C130074G19Rik |
RIKEN cDNA C130074G19 gene |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of C13H1ORF115 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:184,604,123...184,615,233
Ensembl chr 1:184,604,123...184,615,415
|
|
G |
C1qtnf5 |
C1q and tumor necrosis factor related protein 5 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of C1QTNF5 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 9:44,013,067...44,020,484
Ensembl chr 9:44,018,542...44,020,484
|
|
G |
Calca |
calcitonin/calcitonin-related polypeptide, alpha |
increases abundance multiple interactions |
ISO |
CALCA protein modified form results in increased abundance of Cyclic AMP; CALCA protein results in increased abundance of Cyclic AMP CALCA protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]] Isoflurane inhibits the reaction [CALCA protein modified form results in increased abundance of Cyclic AMP]; sevoflurane inhibits the reaction [CALCA protein modified form results in increased abundance of Cyclic AMP] |
CTD |
PMID:15297469 PMID:17295025 PMID:17306419 PMID:18463244 |
|
NCBI chr 7:114,225,223...114,236,145
Ensembl chr 7:114,230,713...114,235,592
|
|
G |
Carm1 |
coactivator-associated arginine methyltransferase 1 |
multiple interactions increases phosphorylation |
ISO |
[Cyclic AMP results in increased phosphorylation of CARM1 protein] promotes the reaction [CARM1 protein binds to ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased expression of TFF1 mRNA]; Cyclic AMP promotes the reaction [CARM1 protein binds to ESR1 protein]; Cyclic AMP promotes the reaction [CARM1 protein binds to TFF1 promoter] |
CTD |
PMID:20360387 |
|
NCBI chr 9:21,458,163...21,500,763
Ensembl chr 9:21,458,190...21,503,919
|
|
G |
Cckbr |
cholecystokinin B receptor |
multiple interactions |
EXP |
CCKBR protein affects the reaction [[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP] |
CTD |
PMID:11880531 |
|
NCBI chr 7:105,075,201...105,085,546
Ensembl chr 7:105,074,938...105,120,105
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
EXP |
Cyclic AMP inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein] |
CTD |
PMID:9863660 |
|
NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CCN2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein; Sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein] |
CTD |
PMID:21693435 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Cd3e |
CD3 antigen, epsilon polypeptide |
decreases phosphorylation |
EXP |
Cyclic AMP results in decreased phosphorylation of CD3E protein |
CTD |
PMID:2824607 |
|
NCBI chr 9:44,910,033...44,920,961
Ensembl chr 9:44,910,038...44,920,925
|
|
G |
Cd3g |
CD3 antigen, gamma polypeptide |
decreases phosphorylation |
EXP |
Cyclic AMP results in decreased phosphorylation of CD3G protein |
CTD |
PMID:2824607 |
|
NCBI chr 9:44,880,870...44,891,729
Ensembl chr 9:44,880,870...44,891,729
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein; [Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein; sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein] |
CTD |
PMID:21693435 |
|
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases response to substance |
EXP |
CEBPB protein results in increased susceptibility to Cyclic AMP |
CTD |
PMID:23097472 |
|
NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338
|
|
G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
multiple interactions increases activity |
ISO EXP |
Cyclic AMP promotes the reaction [CFTR protein results in increased transport of Bicarbonates]; Cyclic AMP promotes the reaction [CFTR protein results in increased transport of Chlorides] CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]; Cyclic AMP affects the localization of and results in increased activity of CFTR protein; Nitric Oxide inhibits the reaction [CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]]; Nocodazole inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein]; Primaquine inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein] Cyclic AMP results in increased activity of CFTR protein Genistein promotes the reaction [Cyclic AMP results in increased activity of CFTR protein mutant form] |
CTD |
PMID:11786964 PMID:12529251 PMID:12556293 PMID:12612912 PMID:15229107 PMID:15371258 More...
|
|
NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767
|
|
G |
Cga |
glycoprotein hormones, alpha subunit |
multiple interactions affects secretion increases abundance |
ISO EXP |
[Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of CGA mRNA CGA protein affects the secretion of Cyclic AMP CGA protein results in increased abundance of Cyclic AMP [CGA protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [CGA protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Cyclic AMP; [CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Colforsin promotes the reaction [CGA protein results in increased abundance of Cyclic AMP]; Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]]; DDT inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP] [ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]; ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:8404651 PMID:20378682 PMID:21642635 PMID:23071612 PMID:26895433 PMID:31132478 PMID:33638691 PMID:37552060 More...
|
|
NCBI chr 4:34,893,779...34,907,374
Ensembl chr 4:34,893,779...34,907,370
|
|
G |
Chsy1 |
chondroitin sulfate synthase 1 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CHSY1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 7:65,759,240...65,823,546
Ensembl chr 7:65,759,263...65,823,546
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
ISO |
[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP (1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP; [Dronabinol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR1 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] |
CTD |
PMID:10422789 PMID:11730719 PMID:17953657 PMID:27429655 |
|
NCBI chr 4:33,923,171...33,948,831
Ensembl chr 4:33,924,593...33,948,831
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions |
ISO |
(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR2 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] |
CTD |
PMID:17558435 PMID:27429655 |
|
NCBI chr 4:135,622,500...135,647,530
Ensembl chr 4:135,622,705...135,647,518
|
|
G |
Cntn1 |
contactin 1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr15:91,949,034...92,239,834
Ensembl chr15:91,949,046...92,239,848
|
|
G |
Cp |
ceruloplasmin |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CP mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:20,011,097...20,063,914
Ensembl chr 3:20,011,218...20,063,309
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein; [Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein; Cyclic AMP promotes the reaction [CREB1 protein binds to CYP1B1 enhancer] |
CTD |
PMID:12859982 PMID:22676303 |
|
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
ISO |
CREBBP protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein] |
CTD |
PMID:20360387 |
|
NCBI chr16:3,899,198...4,031,864
Ensembl chr16:3,899,192...4,031,861
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
ISO |
[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP] CRH protein inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Cholera Toxin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Manganese results in increased chemical synthesis of Cyclic AMP]; Sphingosine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]] |
CTD |
PMID:2153673 PMID:20702571 |
|
NCBI chr 3:19,747,565...19,749,560
Ensembl chr 3:19,747,565...19,749,560
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
multiple interactions |
ISO |
[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:20702571 |
|
NCBI chr11:104,021,289...104,066,349
Ensembl chr11:104,023,681...104,066,349
|
|
G |
Crp |
C-reactive protein, pentraxin-related |
multiple interactions |
EXP |
Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of CRP mRNA] |
CTD |
PMID:22117073 |
|
NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598
|
|
G |
Csf3 |
colony stimulating factor 3 (granulocyte) |
increases expression |
ISO |
Cyclic AMP results in increased expression of CSF3 protein |
CTD |
PMID:7540958 |
|
NCBI chr11:98,591,287...98,594,457
Ensembl chr11:98,592,089...98,594,455
|
|
G |
Csk |
c-src tyrosine kinase |
multiple interactions |
EXP |
CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]; CSK protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP]; CSK protein promotes the reaction [Terbutaline results in increased abundance of Cyclic AMP]; Isoproterenol inhibits the reaction [CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]] |
CTD |
PMID:1699227 |
|
NCBI chr 9:57,533,929...57,560,758
Ensembl chr 9:57,533,929...57,560,914
|
|
G |
Cstb |
cystatin B |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CSTB mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:78,261,504...78,263,456
Ensembl chr10:78,261,503...78,263,456
|
|
G |
Ctsa |
cathepsin A |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CTSA mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:164,674,792...164,682,952
Ensembl chr 2:164,674,793...164,682,952
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions |
ISO |
[Terbutaline results in increased abundance of Cyclic AMP] which results in increased expression of CXCL8 protein |
CTD |
PMID:9258252 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
increases expression multiple interactions |
EXP ISO |
Cyclic AMP results in increased expression of CYP11A1 mRNA Cyclic AMP results in increased expression of CYP11A1 mRNA; Cyclic AMP results in increased expression of CYP11A1 protein myricetin promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA] |
CTD |
PMID:25576683 PMID:28668616 PMID:29228121 |
|
NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO EXP |
[acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein Cyclic AMP results in increased expression of CYP17A1 mRNA |
CTD |
PMID:23084589 PMID:25576683 |
|
NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
Cyclic AMP results in increased expression of CYP19A1 mRNA; Cyclic AMP results in increased expression of CYP19A1 protein [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:29228121 PMID:31953017 |
|
NCBI chr 9:54,073,221...54,175,448
Ensembl chr 9:54,073,221...54,175,394
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA |
CTD |
PMID:32781018 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression multiple interactions |
EXP ISO |
Cyclic AMP results in increased expression of CYP1B1 mRNA; Cyclic AMP results in increased expression of CYP1B1 protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA AHR protein promotes the reaction [Cyclic AMP results in increased expression of CYP1B1 mRNA]; Cyclic AMP promotes the reaction [AHR protein binds to CYP1B1 enhancer]; Cyclic AMP promotes the reaction [CREB1 protein binds to CYP1B1 enhancer] |
CTD |
PMID:12859982 PMID:32781018 |
|
NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490
|
|
G |
Cyp2a5 |
cytochrome P450, family 2, subfamily a, polypeptide 5 |
multiple interactions increases expression |
EXP |
Cyclic AMP promotes the reaction [HNF4A protein binds to CYP2A5 promoter]; Cyclic AMP promotes the reaction [PPARGC1A protein binds to CYP2A5 promoter]; Dactinomycin inhibits the reaction [Cyclic AMP results in increased expression of CYP2A5 mRNA] |
CTD |
PMID:12754101 PMID:18602936 |
|
NCBI chr 7:26,534,764...26,542,689
Ensembl chr 7:26,534,730...26,542,973
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
EXP |
Cyclic AMP results in increased expression of CYP51 mRNA |
CTD |
PMID:25576683 |
|
NCBI chr 5:4,130,674...4,154,697
Ensembl chr 5:4,131,145...4,154,746
|
|
G |
Cyp7b1 |
cytochrome P450, family 7, subfamily b, polypeptide 1 |
decreases expression decreases activity |
ISO |
Cyclic AMP results in decreased expression of CYP7B1 mRNA Cyclic AMP results in decreased activity of CYP7B1 protein |
CTD |
PMID:12029625 |
|
NCBI chr 3:18,126,108...18,298,054
Ensembl chr 3:18,126,114...18,297,502
|
|
G |
Dap |
death-associated protein |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of DAP mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr15:31,224,531...31,274,484
Ensembl chr15:31,224,460...31,274,487
|
|
G |
Ddt |
D-dopachrome tautomerase |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of DDT mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:75,607,067...75,609,208
Ensembl chr10:75,607,064...75,609,248
|
|
G |
Disc1 |
disrupted in schizophrenia 1 |
multiple interactions |
ISO |
Cyclic AMP inhibits the reaction [DISC1 protein binds to PDE4B protein] |
CTD |
PMID:16293762 |
|
NCBI chr 8:125,773,928...125,991,882
Ensembl chr 8:125,780,934...125,988,597
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
affects response to substance |
ISO |
DKK1 protein affects the susceptibility to Cyclic AMP |
CTD |
PMID:21546446 |
|
NCBI chr19:30,523,276...30,526,896
Ensembl chr19:30,523,263...30,527,065
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
increases abundance |
ISO |
DLD protein results in increased abundance of Cyclic AMP |
CTD |
PMID:25981801 |
|
NCBI chr12:31,381,561...31,401,470
Ensembl chr12:31,381,276...31,401,452
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr11:69,908,029...69,938,107
Ensembl chr11:69,907,768...69,938,348
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
ISO |
A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP] [SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP; A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]; SCH 23390 inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]]; SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]]; Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]; Spiperone inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]] |
CTD |
PMID:8558425 PMID:15711596 |
|
NCBI chr13:54,205,202...54,209,677
Ensembl chr13:54,205,202...54,209,724
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
ISO EXP |
[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] [quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP; CCKBR protein affects the reaction [[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP] |
CTD |
PMID:11880531 PMID:17958328 |
|
NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477
|
|
G |
Drd4 |
dopamine receptor D4 |
multiple interactions |
EXP |
[3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine binds to and results in decreased activity of DRD4 protein] inhibits the reaction [Naloxone results in increased abundance of Cyclic AMP] |
CTD |
PMID:15542745 |
|
NCBI chr 7:140,871,931...140,874,868
Ensembl chr 7:140,871,919...140,876,377
|
|
G |
E2f2 |
E2F transcription factor 2 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 4:135,899,585...135,923,368
Ensembl chr 4:135,899,705...135,923,368
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
[Cimetidine results in decreased abundance of Cyclic AMP] inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:17295779 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
[[Eugenol results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP] which results in increased expression of EGR1 mRNA |
CTD |
PMID:12767924 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Ehd2 |
EH-domain containing 2 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of EHD2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 7:15,680,883...15,701,402
Ensembl chr 7:15,680,883...15,701,492
|
|
G |
Endod1 |
endonuclease domain containing 1 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ENDOD1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 9:14,265,286...14,292,538
Ensembl chr 9:14,265,286...14,292,803
|
|
G |
Eno2 |
enolase 2, gamma neuronal |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ENO2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 6:124,737,018...124,746,489
Ensembl chr 6:124,737,016...124,746,636
|
|
G |
Epo |
erythropoietin |
increases expression |
ISO |
Cyclic AMP results in increased expression of EPO protein |
CTD |
PMID:18621143 |
|
NCBI chr 5:137,481,282...137,484,078
Ensembl chr 5:137,481,282...137,531,504
|
|
G |
Errfi1 |
ERBB receptor feedback inhibitor 1 |
increases expression |
ISO |
Cyclic AMP results in increased expression of ERRFI1 mRNA |
CTD |
PMID:1472065 |
|
NCBI chr 4:150,938,253...150,953,346
Ensembl chr 4:150,938,376...150,953,349
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
multiple interactions increases activity |
ISO |
[Cyclic AMP results in increased phosphorylation of CARM1 protein] promotes the reaction [CARM1 protein binds to ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; CREBBP protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; Cyclic AMP promotes the reaction [CARM1 protein binds to ESR1 protein]; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased activity of ESR1 protein] |
CTD |
PMID:19766106 PMID:20360387 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
multiple interactions |
ISO EXP |
ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP] [ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]; ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:19766106 PMID:20378682 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
F2r |
coagulation factor II thrombin receptor |
multiple interactions |
EXP |
[C186 65 binds to and results in increased activity of F2R protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [C186 65 binds to and results in increased activity of F2R protein] which results in decreased chemical synthesis of Cyclic AMP |
CTD |
PMID:22207716 |
|
NCBI chr13:95,738,288...95,754,974
Ensembl chr13:95,738,311...95,754,995
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
multiple interactions |
ISO |
Cyclic AMP promotes the reaction [F2RL1 protein results in increased transport of Chlorides] |
CTD |
PMID:11804840 |
|
NCBI chr13:95,648,226...95,661,748
Ensembl chr13:95,648,240...95,661,735
|
|
G |
F2rl3 |
F2R like thrombin or trypsin receptor 3 |
multiple interactions |
EXP |
[GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] which results in decreased chemical synthesis of Cyclic AMP |
CTD |
PMID:22207716 |
|
NCBI chr 8:73,488,287...73,490,526
Ensembl chr 8:73,488,508...73,490,502
|
|
G |
Fam20c |
FAM20C, golgi associated secretory pathway kinase |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FAM20C mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 5:138,740,836...138,795,818
Ensembl chr 5:138,740,269...138,795,832
|
|
G |
Fcgr3 |
Fc receptor, IgG, low affinity III |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FCGR3 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:170,878,738...170,893,477
Ensembl chr 1:170,878,743...170,892,504
|
|
G |
Fdx1 |
ferredoxin 1 |
multiple interactions increases expression |
EXP |
myricetin promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA] |
CTD |
PMID:28668616 |
|
NCBI chr 9:51,854,323...51,874,902
Ensembl chr 9:51,854,606...51,874,856
|
|
G |
Fig4 |
FIG4 phosphoinositide 5-phosphatase |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FIG4 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:41,064,168...41,179,237
Ensembl chr10:41,064,168...41,179,256
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
multiple interactions increases expression |
ISO EXP |
[Etoposide co-treated with Cyclic AMP] results in increased expression of FOS mRNA Cyclic AMP results in increased expression of FOS mRNA |
CTD |
PMID:10064622 PMID:10711420 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Foxm1 |
forkhead box M1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 6:128,339,957...128,352,849
Ensembl chr 6:128,339,930...128,353,109
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO EXP |
[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA] FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]] |
CTD |
PMID:26847930 PMID:31953017 |
|
NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642
|
|
G |
Fshb |
follicle stimulating hormone beta |
multiple interactions increases abundance increases secretion |
ISO EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of FSHB mRNA; fulvestrant inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; Methoxychlor inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP] FSHB protein results in increased secretion of Cyclic AMP NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]] [FSHB protein co-treated with Testosterone] results in increased chemical synthesis of Cyclic AMP; [FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Benzo(a)pyrene inhibits the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:8404651 PMID:18535249 PMID:23137853 PMID:23583632 PMID:25549949 PMID:26895433 More...
|
|
NCBI chr 2:106,886,331...106,889,996
Ensembl chr 2:106,886,485...106,890,001
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; [FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Benzo(a)pyrene inhibits the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:26895433 |
|
NCBI chr17:89,292,380...89,508,103
Ensembl chr17:89,292,380...89,508,103
|
|
G |
Fzd10 |
frizzled class receptor 10 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 5:128,678,170...128,681,157
Ensembl chr 5:128,677,908...128,681,157
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO EXP |
[Dexamethasone co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA] [Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein] |
CTD |
PMID:22676303 PMID:26847930 |
|
NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729
|
|
G |
Gabpb1 |
GA repeat binding protein, beta 1 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GABPB1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:126,470,832...126,527,184
Ensembl chr 2:126,469,362...126,518,257
|
|
G |
Gabra2 |
gamma-aminobutyric acid type A receptor subunit alpha 2 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 5:71,115,735...71,253,192
Ensembl chr 5:71,114,940...71,253,192
|
|
G |
Gbp2 |
guanylate binding protein 2 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GBP2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:142,326,424...142,343,769
Ensembl chr 3:142,326,363...142,343,769
|
|
G |
Gcg |
glucagon |
multiple interactions increases chemical synthesis increases abundance |
EXP ISO |
[GCG protein modified form binds to and results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP Dietary Fats promotes the reaction [GCG protein results in increased chemical synthesis of Cyclic AMP]; Niclosamide inhibits the reaction [GCG protein results in increased abundance of Cyclic AMP] [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein; [GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP |
CTD |
PMID:6312992 PMID:18669601 PMID:20074626 PMID:25191754 PMID:26964897 |
|
NCBI chr 2:62,304,874...62,313,997
Ensembl chr 2:62,304,874...62,313,994
|
|
G |
Gdnf |
glial cell line derived neurotrophic factor |
multiple interactions |
ISO |
3,9-bis((ethylthio)methyl)-K-252a inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein; [GDNF protein co-treated with Cyclic AMP] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; [GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium; Mazindol inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]; vanoxerine inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:19647008 PMID:33713149 |
|
NCBI chr15:7,839,529...7,867,061
Ensembl chr15:7,840,327...7,867,056
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA |
CTD |
PMID:33713149 |
|
NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738
|
|
G |
Ghrh |
growth hormone releasing hormone |
multiple interactions |
ISO |
[GH-RH(1-29), desaminotyrosyl(1)-ornithyl(12,21)-alpha-aminobutryic acid(15)-norleucyl(27)-aspartyl(28)-agmatine(29)- binds to and results in increased activity of GHRH protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:22308467 |
|
NCBI chr 2:157,171,416...157,190,645
Ensembl chr 2:157,171,417...157,189,426
|
|
G |
Gip |
gastric inhibitory polypeptide |
multiple interactions |
ISO |
[GIP protein binds to and results in increased activity of GIPR protein] which results in increased chemical synthesis of Cyclic AMP |
CTD |
PMID:25191754 |
|
NCBI chr11:95,915,358...95,921,657
Ensembl chr11:95,915,371...95,921,657
|
|
G |
Gipr |
gastric inhibitory polypeptide receptor |
multiple interactions |
ISO |
[GIP protein binds to and results in increased activity of GIPR protein] which results in increased chemical synthesis of Cyclic AMP |
CTD |
PMID:25191754 |
|
NCBI chr 7:18,889,988...18,904,173
Ensembl chr 7:18,889,986...18,900,052
|
|
G |
Gli1 |
GLI-Kruppel family member GLI1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr10:127,165,751...127,177,448
Ensembl chr10:127,165,751...127,177,843
|
|
G |
Glipr2 |
GLI pathogenesis-related 2 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GLIPR2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 4:43,957,702...43,979,118
Ensembl chr 4:43,957,401...43,979,118
|
|
G |
Glp1r |
glucagon-like peptide 1 receptor |
multiple interactions |
EXP ISO |
[GCG protein modified form binds to and results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein; [GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP |
CTD |
PMID:18669601 PMID:25191754 |
|
NCBI chr17:31,120,841...31,155,484
Ensembl chr17:31,120,791...31,159,765
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
multiple interactions |
EXP |
[[IER3 protein affects the chemical synthesis of Reactive Oxygen Species] which results in increased expression of GNAI2] which results in decreased chemical synthesis of Cyclic AMP |
CTD |
PMID:20713914 |
|
NCBI chr 9:107,491,324...107,512,542
Ensembl chr 9:107,491,324...107,512,566
|
|
G |
Gnal |
guanine nucleotide binding protein, alpha stimulating, olfactory type |
multiple interactions |
ISO |
[[GNAL protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:15598656 |
|
NCBI chr18:67,221,369...67,359,863
Ensembl chr18:67,221,287...67,359,863
|
|
G |
Gnas |
GNAS complex locus |
multiple interactions |
ISO EXP |
[[GNAS protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP; GNAS protein promotes the reaction [[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP] [[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:11895442 PMID:15598656 PMID:23022524 |
|
NCBI chr 2:174,126,113...174,188,537
Ensembl chr 2:174,126,113...174,188,537
|
|
G |
Gpbar1 |
G protein-coupled bile acid receptor 1 |
multiple interactions |
EXP ISO |
[[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP [Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; [Colforsin binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; [Lithocholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:17963371 PMID:23022524 |
|
NCBI chr 1:74,316,269...74,318,868
Ensembl chr 1:74,317,709...74,318,783
|
|
G |
Gpc3 |
glypican 3 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GPC3 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr X:51,361,303...51,702,851
Ensembl chr X:51,361,303...51,702,827
|
|
G |
Greb1l |
growth regulation by estrogen in breast cancer-like |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GREB1L mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr18:10,324,933...10,562,945
Ensembl chr18:10,325,177...10,562,940
|
|
G |
Gria2 |
glutamate receptor, ionotropic, AMPA2 (alpha 2) |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 3:80,588,757...80,711,534
Ensembl chr 3:80,588,757...80,710,142
|
|
G |
Grin1 |
glutamate receptor, ionotropic, NMDA1 (zeta 1) |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 2:25,181,189...25,209,199
Ensembl chr 2:25,181,193...25,209,199
|
|
G |
Grin2a |
glutamate receptor, ionotropic, NMDA2A (epsilon 1) |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA |
CTD |
PMID:33713149 |
|
NCBI chr16:9,385,765...9,813,744
Ensembl chr16:9,385,762...9,813,424
|
|
G |
Grin2b |
glutamate receptor, ionotropic, NMDA2B (epsilon 2) |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 6:135,690,219...136,150,658
Ensembl chr 6:135,690,231...136,150,509
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
multiple interactions |
ISO |
[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein] |
CTD |
PMID:25191754 |
|
NCBI chr19:4,336,029...4,356,356
Ensembl chr19:4,336,029...4,356,250
|
|
G |
Grn |
granulin |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GRN mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr11:102,321,333...102,327,635
Ensembl chr11:102,321,141...102,327,874
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
GSK3B protein affects the reaction [Deamino Arginine Vasopressin results in increased abundance of Cyclic AMP] |
CTD |
PMID:20056751 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
Gtpbp2 |
GTP binding protein 2 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GTPBP2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr17:46,470,153...46,480,294
Ensembl chr17:46,471,958...46,480,296
|
|
G |
Gypc |
glycophorin C |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GYPC mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr18:32,661,373...32,693,087
Ensembl chr18:32,661,375...32,693,087
|
|
G |
H2bc21 |
H2B clustered histone 21 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HIST2H2BE mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:96,128,435...96,131,057
Ensembl chr 3:96,128,435...96,131,054
|
|
G |
Hcar2 |
hydroxycarboxylic acid receptor 2 |
decreases abundance |
ISO |
HCAR3 protein results in decreased abundance of Cyclic AMP |
CTD |
PMID:19237584 |
|
NCBI chr 5:124,001,633...124,003,579
Ensembl chr 5:124,001,633...124,003,562
|
|
G |
Hdac2 |
histone deacetylase 2 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HDAC2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:36,850,293...36,877,885
Ensembl chr10:36,850,540...36,877,885
|
|
G |
Hdac6 |
histone deacetylase 6 |
affects abundance |
EXP |
HDAC6 protein affects the abundance of Cyclic AMP |
CTD |
PMID:28887310 |
|
NCBI chr X:7,796,355...7,814,284
Ensembl chr X:7,796,359...7,814,128
|
|
G |
Hes3 |
hes family bHLH transcription factor 3 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 4:152,369,707...152,376,133
Ensembl chr 4:152,370,429...152,376,119
|
|
G |
Hivep2 |
human immunodeficiency virus type I enhancer binding protein 2 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HIVEP2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:13,841,819...14,027,122
Ensembl chr10:13,841,819...14,027,118
|
|
G |
Hnf4a |
hepatic nuclear factor 4, alpha |
multiple interactions |
EXP |
Cyclic AMP promotes the reaction [HNF4A protein binds to CYP2A5 promoter] |
CTD |
PMID:18602936 |
|
NCBI chr 2:163,348,731...163,414,827
Ensembl chr 2:163,348,728...163,414,830
|
|
G |
Hoxb1 |
homeobox B1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr11:96,256,547...96,259,082
Ensembl chr11:96,256,578...96,259,082
|
|
G |
Hp |
haptoglobin |
multiple interactions |
EXP |
Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of HP mRNA] |
CTD |
PMID:22117073 |
|
NCBI chr 8:110,301,760...110,305,804
Ensembl chr 8:110,301,760...110,305,804
|
|
G |
Hrh1 |
histamine receptor H1 |
multiple interactions |
ISO |
1-Methyl-3-isobutylxanthine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]]; HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]; Triprolidine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]] |
CTD |
PMID:2419744 |
|
NCBI chr 6:114,374,897...114,459,432
Ensembl chr 6:114,374,897...114,460,257
|
|
G |
Hrh2 |
histamine receptor H2 |
increases abundance multiple interactions |
ISO |
HRH2 protein results in increased abundance of Cyclic AMP [Cimetidine binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cyclic AMP; [Dimaprit binds to and results in increased activity of HRH2 protein] which results in increased abundance of Cyclic AMP; [Histamine binds to and results in increased activity of HRH2 protein] which results in increased abundance of Cyclic AMP; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cimetidine]; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in increased activity of HRH2 protein] which results in increased abundance of Histamine]; Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12A protein]; Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12B protein]; Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP]]; HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]; HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP] |
CTD |
PMID:9187264 PMID:9681472 PMID:15843518 |
|
NCBI chr13:54,345,990...54,390,201
Ensembl chr13:54,346,148...54,390,199
|
|
G |
Hrh3 |
histamine receptor H3 |
multiple interactions |
ISO |
[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; ciproxifan inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; thioperamide inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:21276809 |
|
NCBI chr 2:179,741,258...179,746,264
Ensembl chr 2:179,741,258...179,746,281
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
increases expression |
EXP |
Cyclic AMP results in increased expression of HSD3B1 mRNA |
CTD |
PMID:25576683 |
|
NCBI chr 3:98,749,672...98,767,110
Ensembl chr 3:98,759,510...98,767,110
|
|
G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A |
multiple interactions |
ISO |
[JB-788 binds to and results in increased activity of HTR1A protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Arachidonic Acid metabolite inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Melitten inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:11356925 PMID:20580787 |
|
NCBI chr13:105,580,040...105,584,630
Ensembl chr13:105,580,147...105,584,630
|
|
G |
Htr1b |
5-hydroxytryptamine (serotonin) receptor 1B |
multiple interactions |
ISO |
HTR1B affects the reaction [almotriptan inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:11134654 |
|
NCBI chr 9:81,510,344...81,515,885
Ensembl chr 9:81,510,344...81,515,881
|
|
G |
Htr6 |
5-hydroxytryptamine (serotonin) receptor 6 |
increases abundance multiple interactions |
EXP |
HTR6 protein results in increased abundance of Cyclic AMP Serotonin promotes the reaction [HTR6 protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:11406289 |
|
NCBI chr 4:138,787,017...138,802,881
Ensembl chr 4:138,788,419...138,802,881
|
|
G |
Htr7 |
5-hydroxytryptamine (serotonin) receptor 7 |
increases abundance multiple interactions |
ISO |
HTR7 results in increased abundance of Cyclic AMP [3,N-dimethyl-N-(1-methyl-3-(4-methylpiperidin-1-yl)propyl)benzenesulfonamide binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [5-carboxamidotryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [5-Methoxytryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Clozapine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Ketanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Lisuride binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [mesulergine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] which results in decreased abundance of Cyclic AMP; [Methoxydimethyltryptamines binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Mianserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Risperidone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Ritanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Serotonin binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Spiperone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [volinanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP] |
CTD |
PMID:10720076 PMID:14578406 PMID:19509219 |
|
NCBI chr19:35,935,815...36,035,533
Ensembl chr19:35,936,134...36,034,907
|
|
G |
Htra1 |
HtrA serine peptidase 1 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HTRA1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 7:130,537,933...130,587,388
Ensembl chr 7:130,537,841...130,587,390
|
|
G |
Idh2 |
isocitrate dehydrogenase 2 (NADP+), mitochondrial |
multiple interactions increases abundance |
EXP |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Cyclic AMP] |
CTD |
PMID:27469509 |
|
NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein |
CTD |
PMID:32781018 |
|
NCBI chr 8:25,074,148...25,086,987
Ensembl chr 8:25,074,152...25,087,025
|
|
G |
Ier3 |
immediate early response 3 |
multiple interactions affects response to substance |
ISO EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IER3 mRNA] IER3 protein affects the susceptibility to Cyclic AMP [[IER3 protein affects the chemical synthesis of Reactive Oxygen Species] which results in increased expression of GNAI2] which results in decreased chemical synthesis of Cyclic AMP; IER3 protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]; Pertussis Toxin affects the reaction [IER3 protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]] |
CTD |
PMID:19414516 PMID:20713914 |
|
NCBI chr17:36,132,605...36,133,803
Ensembl chr17:36,132,576...36,133,815
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]] |
CTD |
PMID:32781018 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions |
ISO |
2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; [Cyclic AMP co-treated with Estradiol co-treated with Progesterone] results in increased expression of IGFBP1 mRNA; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA] |
CTD |
PMID:31953017 PMID:32446389 PMID:32781018 |
|
NCBI chr11:7,147,787...7,152,546
Ensembl chr11:7,147,782...7,152,546
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IGFBP5 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:72,897,224...72,914,024
Ensembl chr 1:72,897,091...72,914,043
|
|
G |
Il12a |
interleukin 12a |
multiple interactions |
ISO |
Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12A protein] |
CTD |
PMID:15843518 |
|
NCBI chr 3:68,597,977...68,605,881
Ensembl chr 3:68,597,977...68,605,880
|
|
G |
Il12b |
interleukin 12b |
multiple interactions |
ISO |
Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12B protein] |
CTD |
PMID:15843518 |
|
NCBI chr11:44,290,890...44,305,504
Ensembl chr11:44,290,890...44,304,860
|
|
G |
Il15ra |
interleukin 15 receptor, alpha chain |
multiple interactions decreases expression |
EXP |
[Metformin co-treated with Cyclic AMP] results in decreased expression of IL15RA mRNA; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in decreased expression of IL15RA mRNA] |
CTD |
PMID:22117073 |
|
NCBI chr 2:11,709,992...11,739,129
Ensembl chr 2:11,710,101...11,739,128
|
|
G |
Il17re |
interleukin 17 receptor E |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IL17RE mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 6:113,435,659...113,447,719
Ensembl chr 6:113,435,445...113,447,719
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases abundance |
ISO EXP |
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; Ibuprofen inhibits the reaction [IL1B protein results in increased abundance of Cyclic AMP]; KT 5720 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; KT 5823 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; Rolipram promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP] Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of CRP mRNA]; Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of HP mRNA]; Cyclic AMP promotes the reaction [IL1B protein results in increased expression of IL1RN mRNA] |
CTD |
PMID:8904084 PMID:17709599 PMID:22117073 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
multiple interactions increases expression |
EXP |
Cyclic AMP promotes the reaction [IL1B protein results in increased expression of IL1RN mRNA]; Cyclic AMP promotes the reaction [Metformin results in increased expression of IL1RN mRNA]; Metformin promotes the reaction [Cyclic AMP results in increased expression of IL1RN mRNA]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in increased expression of IL1RN mRNA] |
CTD |
PMID:22117073 |
|
NCBI chr 2:24,226,872...24,241,503
Ensembl chr 2:24,226,865...24,241,506
|
|
G |
Il4 |
interleukin 4 |
increases chemical synthesis multiple interactions |
ISO |
IL4 protein results in increased chemical synthesis of Cyclic AMP Ketoconazole inhibits the reaction [IL4 protein results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:12230500 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
Cyclic AMP analog results in increased expression of IL6 mRNA |
CTD |
PMID:10469353 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Inhba |
inhibin beta-A |
increases secretion |
ISO |
Cyclic AMP results in increased secretion of INHBA protein |
CTD |
PMID:20074812 |
|
NCBI chr13:16,178,841...16,206,194
Ensembl chr13:16,186,436...16,206,206
|
|
G |
Inhbe |
inhibin beta-E |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA |
CTD |
PMID:33713149 |
|
NCBI chr10:127,185,271...127,187,717
Ensembl chr10:127,184,726...127,190,280
|
|
G |
Ins1 |
insulin I |
multiple interactions |
EXP ISO |
[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein] [Theophylline co-treated with INS1 protein] results in decreased abundance of Cyclic AMP; INS1 protein inhibits the reaction [[Theophylline co-treated with Norepinephrine] results in increased abundance of Cyclic AMP]; INS1 protein inhibits the reaction [[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP] |
CTD |
PMID:4306506 PMID:26847930 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Iqgap1 |
IQ motif containing GTPase activating protein 1 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IQGAP1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 7:80,361,331...80,453,288
Ensembl chr 7:80,361,331...80,475,722
|
|
G |
Irf6 |
interferon regulatory factor 6 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IRF6 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:192,835,420...192,854,344
Ensembl chr 1:192,835,419...192,854,331
|
|
G |
Itgb1 |
integrin beta 1 (fibronectin receptor beta) |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ITGB1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681
|
|
G |
Jun |
jun proto-oncogene |
multiple interactions |
ISO |
[Etoposide co-treated with Cyclic AMP] results in increased expression of JUN mRNA |
CTD |
PMID:10711420 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Kcnd2 |
potassium voltage-gated channel, Shal-related family, member 2 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of KCND2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 6:21,212,101...21,729,804
Ensembl chr 6:21,215,502...21,729,804
|
|
G |
Kif15 |
kinesin family member 15 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of KIF15 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 9:122,780,146...122,847,798
Ensembl chr 9:122,780,111...122,847,798
|
|
G |
Kng1 |
kininogen 1 |
increases abundance |
ISO |
KNG1 results in increased abundance of Cyclic AMP |
CTD |
PMID:15750287 |
|
NCBI chr16:22,876,970...22,900,828
Ensembl chr16:22,876,615...22,900,828
|
|
G |
Lamp1 |
lysosomal-associated membrane protein 1 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LAMP1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 8:13,209,161...13,225,338
Ensembl chr 8:13,209,161...13,225,338
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 3:130,903,972...131,018,006
Ensembl chr 3:130,904,120...131,018,005
|
|
G |
Lep |
leptin |
increases abundance multiple interactions increases expression |
ISO EXP |
LEP protein results in increased abundance of Cyclic AMP 3-(5-tert-butylisoxazol-3-yl)-2-((3-chlorophenyl)hydrazono)-3-oxopropionitrile inhibits the reaction [Cyclic AMP analog results in increased expression of LEP mRNA] |
CTD |
PMID:11342529 PMID:27381457 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Lhb |
luteinizing hormone beta |
multiple interactions increases abundance increases chemical synthesis affects secretion |
ISO |
5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; [Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP; [Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP; [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of LHB mRNA; [LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP; CRH protein inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]; Masoprocol inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; Sphingosine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Sphingosine inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Tetradecanoylphorbol Acetate inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP] CGB3 protein results in increased chemical synthesis of Cyclic AMP; LHB protein results in increased chemical synthesis of Cyclic AMP LHB protein affects the secretion of Cyclic AMP [LHB protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [LHB protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Cyclic AMP; DDT inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:2153673 PMID:6430271 PMID:8404651 PMID:23071612 PMID:33638691 |
|
NCBI chr 7:45,070,370...45,071,278
Ensembl chr 7:45,070,244...45,071,321
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
multiple interactions |
ISO EXP |
[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP] [ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:19766106 PMID:20378682 |
|
NCBI chr17:89,023,812...89,099,487
Ensembl chr17:89,023,909...89,099,418
|
|
G |
Lipe |
lipase, hormone sensitive |
increases activity |
ISO |
Cyclic AMP results in increased activity of LIPE protein |
CTD |
PMID:7155675 |
|
NCBI chr 7:25,078,952...25,097,911
Ensembl chr 7:25,078,952...25,098,135
|
|
G |
Lmna |
lamin A |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LMNA mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:88,388,455...88,413,842
Ensembl chr 3:88,387,454...88,417,263
|
|
G |
Lurap1l |
leucine rich adaptor protein 1-like |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LURAP1L mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 4:80,828,923...80,872,538
Ensembl chr 4:80,828,883...80,873,865
|
|
G |
Man1a |
mannosidase 1, alpha |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of MAN1A mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:53,780,881...53,952,712
Ensembl chr10:53,780,881...53,952,705
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein |
CTD |
PMID:33713149 |
|
NCBI chr 1:66,214,337...66,481,742
Ensembl chr 1:66,214,432...66,481,742
|
|
G |
Mc2r |
melanocortin 2 receptor |
multiple interactions |
ISO |
[acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in decreased expression of MC2R mRNA |
CTD |
PMID:23084589 |
|
NCBI chr18:68,539,970...68,562,391
Ensembl chr18:68,539,978...68,562,391
|
|
G |
Msantd3 |
Myb/SANT-like DNA-binding domain containing 3 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of MSANTD3 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 4:48,539,532...48,565,892
Ensembl chr 4:48,539,935...48,561,919
|
|
G |
Ndufb11 |
NADH:ubiquinone oxidoreductase subunit B11 |
increases phosphorylation multiple interactions |
ISO |
Cyclic AMP results in increased phosphorylation of NDUFB11 protein Zalcitabine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein]; Zidovudine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein] |
CTD |
PMID:17904600 |
|
NCBI chr X:20,481,565...20,483,858
Ensembl chr X:20,481,565...20,483,858
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases expression |
ISO |
[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA; [Isoproterenol results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA Cyclic AMP results in increased expression of NGF mRNA |
CTD |
PMID:2174743 PMID:2853697 |
|
NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329
|
|
G |
Nog |
noggin |
multiple interactions |
EXP |
NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]] |
CTD |
PMID:23137853 |
|
NCBI chr11:89,191,464...89,193,385
Ensembl chr11:89,191,464...89,193,158
|
|
G |
Npl |
N-acetylneuraminate pyruvate lyase |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of NPL mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:153,378,762...153,425,460
Ensembl chr 1:153,378,761...153,425,791
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
decreases expression multiple interactions |
EXP |
Cyclic AMP results in decreased expression of NR0B1 mRNA Verapamil promotes the reaction [Cyclic AMP results in decreased expression of NR0B1 mRNA] |
CTD |
PMID:19822634 |
|
NCBI chr X:85,235,381...85,239,553
Ensembl chr X:85,235,370...85,239,553
|
|
G |
Ntan1 |
N-terminal Asn amidase |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of NTAN1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr16:13,636,629...13,653,314
Ensembl chr16:13,636,709...13,653,315
|
|
G |
Oat |
ornithine aminotransferase |
increases activity multiple interactions increases expression |
ISO |
Cyclic AMP results in increased activity of OAT protein Deoxyglucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Dihydroxyacetone inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Fructose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Fructose inhibits the reaction [Cyclic AMP results in increased expression of OAT mRNA]; Galactose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Glucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Glycerol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Inositol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Mannitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Mannose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Rhamnose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Ribose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Sorbitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Sorbose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Xylitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein] |
CTD |
PMID:2824512 PMID:2827574 |
|
NCBI chr 7:132,159,204...132,178,127
Ensembl chr 7:132,159,207...132,178,127
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions |
ISO |
[7-benzylidenenaltrexone binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [[Naloxone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [[Naltrexone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [chlornaltrexamine binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [clocinnamox binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [nalmefene binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP |
CTD |
PMID:11413242 |
|
NCBI chr10:6,708,593...6,988,209
Ensembl chr10:6,708,506...6,988,198
|
|
G |
Or51a5 |
olfactory receptor family 51 subfamily A member 5 |
multiple interactions |
EXP |
[pelargonic acid results in increased activity of OR51A5 protein] which results in increased abundance of Cyclic AMP; octanoic acid promotes the reaction [[pelargonic acid results in increased activity of OR51A5 protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:15598656 |
|
NCBI chr 7:102,771,036...102,771,989
Ensembl chr 7:102,767,610...102,774,845
|
|
G |
Or55b4 |
olfactory receptor family 55 subfamily B member 4 |
multiple interactions |
EXP |
[azelaic acid results in increased activity of OR55B4 protein] which results in increased abundance of Cyclic AMP; octanoic acid promotes the reaction [[azelaic acid results in increased activity of OR55B4 protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:15598656 |
|
NCBI chr 7:102,133,321...102,137,514
Ensembl chr 7:102,131,238...102,137,520
|
|
G |
Or5d18 |
olfactory receptor family 5 subfamily D member 18 |
multiple interactions |
EXP |
[[Eugenol results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP] which results in increased expression of EGR1 mRNA; [Eugenol binds to and results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP; [Eugenol results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:12767924 PMID:15716417 |
|
NCBI chr 2:87,864,540...87,865,481
Ensembl chr 2:87,862,632...87,868,043
|
|
G |
Or6e1 |
olfactory receptor family 6 subfamily E member 1 |
multiple interactions |
EXP ISO |
[citronellal results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP [[GNAL protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP; [[GNAS protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:15598656 |
|
NCBI chr14:54,519,353...54,520,382
Ensembl chr14:54,515,710...54,522,396
|
|
G |
Os9 |
amplified in osteosarcoma |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of OS9 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:126,928,880...126,957,029
Ensembl chr10:126,931,519...126,957,000
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1, cytosolic |
increases expression multiple interactions |
ISO EXP |
Cyclic AMP results in increased expression of PCK1 mRNA [Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein] [Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; Hydrogen Peroxide inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; ochratoxin A inhibits the reaction [Cyclic AMP results in increased expression of PCK1 mRNA]; sodium arsenite inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA] |
CTD |
PMID:2569870 PMID:8971075 PMID:10446394 PMID:22117073 PMID:22676303 PMID:26847930 More...
|
|
NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066
|
|
G |
Pde10a |
phosphodiesterase 10A |
multiple interactions increases hydrolysis |
ISO |
Cyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]; Cyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:10373451 |
|
NCBI chr17:8,742,719...9,205,480
Ensembl chr17:8,744,204...9,205,480
|
|
G |
Pde11a |
phosphodiesterase 11A |
increases hydrolysis |
ISO |
PDE11A protein results in increased hydrolysis of Cyclic AMP |
CTD |
PMID:10725373 |
|
NCBI chr 2:75,816,152...76,169,501
Ensembl chr 2:75,819,485...76,169,118
|
|
G |
Pde4b |
phosphodiesterase 4B, cAMP specific |
multiple interactions |
EXP ISO |
[[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; [S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP [Bresol results in decreased activity of PDE4B protein] which results in increased abundance of Cyclic AMP; Cyclic AMP inhibits the reaction [DISC1 protein binds to PDE4B protein] |
CTD |
PMID:16293762 PMID:21266552 PMID:21854221 |
|
NCBI chr 4:101,944,529...102,464,459
Ensembl chr 4:101,944,740...102,464,456
|
|
G |
Pde7a |
phosphodiesterase 7A |
multiple interactions increases hydrolysis |
ISO |
1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; Papaverine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:10618442 PMID:10814504 |
|
NCBI chr 3:19,277,272...19,365,486
Ensembl chr 3:19,277,272...19,365,486
|
|
G |
Pde7b |
phosphodiesterase 7B |
increases hydrolysis multiple interactions |
ISO EXP |
PDE7B protein results in increased hydrolysis of Cyclic AMP 1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; E 4021 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; vinpocetine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP] 1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Papaverine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:10618442 PMID:10814504 PMID:10872825 |
|
NCBI chr10:20,272,798...20,600,824
Ensembl chr10:20,273,750...20,600,824
|
|
G |
Pde8a |
phosphodiesterase 8A |
multiple interactions increases metabolic processing increases hydrolysis |
ISO EXP |
Dipyridamole inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP]; E 4021 inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP] PDE8A protein results in increased hydrolysis of Cyclic AMP Dipyridamole inhibits the reaction [PDE8A protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:9671792 PMID:12681444 |
|
NCBI chr 7:80,863,013...80,984,283
Ensembl chr 7:80,863,344...80,984,281
|
|
G |
Pde8b |
phosphodiesterase 8B |
multiple interactions increases metabolic processing increases hydrolysis |
ISO |
9-(2-hydroxy-3-nonyl)adenine inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; E 4021 inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; Sildenafil Citrate inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP] |
CTD |
PMID:9784418 PMID:12681444 |
|
NCBI chr13:95,160,962...95,386,904
Ensembl chr13:95,160,962...95,386,844
|
|
G |
Pde9a |
phosphodiesterase 9A |
increases hydrolysis |
ISO |
PDE9A protein results in increased hydrolysis of Cyclic AMP |
CTD |
PMID:9624146 |
|
NCBI chr17:31,605,079...31,695,284
Ensembl chr17:31,605,184...31,695,284
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase, isoenzyme 1 |
multiple interactions affects abundance |
EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; [PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP]; tubacin affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; tubastatin A affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; W 7 affects the reaction [PDK1 protein affects the abundance of Cyclic AMP] |
CTD |
PMID:28887310 |
|
NCBI chr 2:71,703,398...71,734,202
Ensembl chr 2:71,703,568...71,734,202
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
multiple interactions |
ISO |
PEBP1 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP] |
CTD |
PMID:26670611 |
|
NCBI chr 5:117,420,716...117,425,629
Ensembl chr 5:117,420,719...117,425,690
|
|
G |
Pfn2 |
profilin 2 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of PFN2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:57,749,316...57,755,178
Ensembl chr 3:57,749,316...57,755,500
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]] |
CTD |
PMID:37552060 |
|
NCBI chr 9:8,890,017...8,968,612
Ensembl chr 9:8,899,834...8,968,612
|
|
G |
Pkia |
protein kinase inhibitor, alpha |
multiple interactions |
ISO |
[PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PKIA protein] |
CTD |
PMID:29669941 |
|
NCBI chr 3:7,431,695...7,510,426
Ensembl chr 3:7,431,729...7,510,426
|
|
G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
increases expression multiple interactions |
ISO |
Cyclic AMP results in increased expression of PLA2G4A mRNA; Cyclic AMP results in increased expression of PLA2G4A protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of PLA2G4A mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of PLA2G4A protein] |
CTD |
PMID:22187434 |
|
NCBI chr 1:149,705,369...149,837,041
Ensembl chr 1:149,705,369...149,837,041
|
|
G |
Pomc |
pro-opiomelanocortin-alpha |
multiple interactions increases abundance |
ISO EXP |
[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP; INS1 protein inhibits the reaction [[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP] POMC protein modified form results in increased abundance of Cyclic AMP Quercetin analog inhibits the reaction [POMC protein modified form results in increased abundance of Cyclic AMP] |
CTD |
PMID:4306506 PMID:26586997 |
|
NCBI chr12:4,004,945...4,010,643
Ensembl chr12:4,004,951...4,010,642
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases expression |
EXP |
Cyclic AMP results in increased expression of POR mRNA |
CTD |
PMID:25576683 |
|
NCBI chr 5:135,698,894...135,764,180
Ensembl chr 5:135,698,887...135,764,180
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
multiple interactions increases expression |
EXP ISO |
Cyclic AMP promotes the reaction [PPARGC1A protein binds to CYP2A5 promoter]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in decreased expression of IL15RA mRNA]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in increased expression of IL1RN mRNA] [Dexamethasone co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein] Cyclic AMP results in increased expression of PPARGC1A mRNA |
CTD |
PMID:18602936 PMID:22117073 PMID:22676303 |
|
NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068
|
|
G |
Ppp1r14b |
protein phosphatase 1, regulatory inhibitor subunit 14B |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of PPP1R14B mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr19:6,952,416...6,954,692
Ensembl chr19:6,952,336...6,954,692
|
|
G |
Prkacb |
protein kinase, cAMP dependent, catalytic, beta |
affects response to substance multiple interactions |
ISO |
PRKACB protein mutant form affects the susceptibility to Cyclic AMP [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PKIA protein]; [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] |
CTD |
PMID:29669941 |
|
NCBI chr 3:146,435,334...146,518,691
Ensembl chr 3:146,435,329...146,518,745
|
|
G |
Prkar1a |
protein kinase, cAMP dependent regulatory, type I, alpha |
multiple interactions |
ISO |
[PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] |
CTD |
PMID:29669941 |
|
NCBI chr11:109,539,849...109,560,489
Ensembl chr11:109,540,231...109,560,482
|
|
G |
Prkar2a |
protein kinase, cAMP dependent regulatory, type II alpha |
multiple interactions |
ISO |
Clozapine inhibits the reaction [Cyclic AMP binds to PRKAR2A protein]; Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2A protein] |
CTD |
PMID:11907174 |
|
NCBI chr 9:108,569,342...108,627,643
Ensembl chr 9:108,566,513...108,627,635
|
|
G |
Prkar2b |
protein kinase, cAMP dependent regulatory, type II beta |
multiple interactions |
ISO |
Clozapine inhibits the reaction [Cyclic AMP binds to PRKAR2B protein]; Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2B protein] |
CTD |
PMID:11907174 |
|
NCBI chr12:32,008,468...32,111,639
Ensembl chr12:32,008,475...32,111,295
|
|
G |
Prl |
prolactin |
multiple interactions increases secretion |
ISO |
[Atrazine results in increased abundance of Cyclic AMP] which results in increased secretion of PRL protein 2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; [Cyclic AMP co-treated with Estradiol co-treated with Progesterone] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA] Cyclic AMP results in increased secretion of PRL protein |
CTD |
PMID:20074812 PMID:23022511 PMID:31953017 PMID:32446389 PMID:32781018 |
|
NCBI chr13:27,241,553...27,249,187
Ensembl chr13:27,241,553...27,249,188
|
|
G |
Prok1 |
prokineticin 1 |
affects response to substance |
ISO |
PROK1 protein affects the susceptibility to Cyclic AMP |
CTD |
PMID:21546446 |
|
NCBI chr 3:107,139,232...107,147,023
Ensembl chr 3:107,140,113...107,147,023
|
|
G |
Ptgdr2 |
prostaglandin D2 receptor 2 |
multiple interactions |
EXP |
[5-hydroxyindomethacin binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP; [Indomethacin binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP; [sulindac sulfide binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP |
CTD |
PMID:15563582 |
|
NCBI chr19:10,901,883...10,919,875
Ensembl chr19:10,914,524...10,919,875
|
|
G |
Ptger2 |
prostaglandin E receptor 2 (subtype EP2) |
multiple interactions |
ISO |
[Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:23526216 |
|
NCBI chr14:45,225,568...45,241,277
Ensembl chr14:45,225,652...45,241,277
|
|
G |
Ptger3 |
prostaglandin E receptor 3 (subtype EP3) |
multiple interactions |
EXP |
[Dinoprostone results in increased activity of PTGER3 protein] which results in decreased abundance of Cyclic AMP |
CTD |
PMID:10357836 |
|
NCBI chr 3:157,272,459...157,350,392
Ensembl chr 3:157,272,529...157,351,525
|
|
G |
Ptger4 |
prostaglandin E receptor 4 (subtype EP4) |
multiple interactions |
ISO |
[Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:23526216 |
|
NCBI chr15:5,262,880...5,273,668
Ensembl chr15:5,236,142...5,273,668
|
|
G |
Ptgir |
prostaglandin I receptor (IP) |
multiple interactions |
ISO |
[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP; GNAS protein promotes the reaction [[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:11895442 |
|
NCBI chr 7:16,640,442...16,644,828
Ensembl chr 7:16,640,415...16,644,830
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Cyclic AMP] |
CTD |
PMID:21873648 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Pth |
parathyroid hormone |
increases abundance |
ISO |
PTH protein results in increased abundance of Cyclic AMP |
CTD |
PMID:26851681 |
|
NCBI chr 7:112,984,783...112,987,879
Ensembl chr 7:112,984,787...112,987,777
|
|
G |
Pthlh |
parathyroid hormone-like peptide |
increases abundance |
ISO |
PTHLH protein results in increased abundance of Cyclic AMP |
CTD |
PMID:10600786 |
|
NCBI chr 6:147,153,607...147,165,511
Ensembl chr 6:147,153,599...147,165,681
|
|
G |
Ptma |
prothymosin alpha |
increases abundance |
EXP |
PTMA protein results in increased abundance of Cyclic AMP |
CTD |
PMID:9147362 |
|
NCBI chr 1:86,454,442...86,458,434
Ensembl chr 1:86,454,448...86,458,434
|
|
G |
Rab3b |
RAB3B, member RAS oncogene family |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RAB3B mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 4:108,736,267...108,800,521
Ensembl chr 4:108,736,260...108,800,521
|
|
G |
Rap1a |
RAS-related protein 1a |
increases activity |
ISO |
Cyclic AMP results in increased activity of RAP1A protein |
CTD |
PMID:24701590 |
|
NCBI chr 3:105,634,576...105,708,740
Ensembl chr 3:105,634,583...105,708,652
|
|
G |
Rap1b |
RAS related protein 1b |
multiple interactions |
ISO |
[Pentoxifylline results in increased abundance of Cyclic AMP] results in increased abundance of [RAP1B protein binds to Guanosine Triphosphate] |
CTD |
PMID:21693435 |
|
NCBI chr10:117,650,502...117,681,879
Ensembl chr10:117,649,776...117,681,940
|
|
G |
Rbfox3 |
RNA binding protein, fox-1 homolog (C. elegans) 3 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein |
CTD |
PMID:33713149 |
|
NCBI chr11:118,380,586...118,802,423
Ensembl chr11:118,380,588...118,802,423
|
|
G |
Rbm12 |
RNA binding motif protein 12 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RBM12 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:155,933,876...155,953,847
Ensembl chr 2:155,933,878...155,953,898
|
|
G |
Rgl1 |
ral guanine nucleotide dissociation stimulator,-like 1 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RGL1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:152,392,513...152,642,056
Ensembl chr 1:152,392,511...152,642,102
|
|
G |
Rmdn3 |
regulator of microtubule dynamics 3 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RMDN3 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:118,967,479...118,987,515
Ensembl chr 2:118,967,482...118,987,515
|
|
G |
S100b |
S100 protein, beta polypeptide, neural |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein |
CTD |
PMID:33713149 |
|
NCBI chr10:76,089,670...76,097,153
Ensembl chr10:76,089,687...76,096,993
|
|
G |
Scn2a |
sodium channel, voltage-gated, type II, alpha |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 2:65,451,108...65,597,791
Ensembl chr 2:65,451,115...65,597,791
|
|
G |
Sct |
secretin |
multiple interactions increases abundance |
ISO |
Epinephrine inhibits the reaction [SCT protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:6312992 |
|
NCBI chr 7:140,858,243...140,859,082
Ensembl chr 7:140,858,243...140,859,046
|
|
G |
Sdc1 |
syndecan 1 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SDC1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr12:8,821,396...8,843,716
Ensembl chr12:8,821,323...8,843,715
|
|
G |
Slc17a6 |
solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 7:51,271,578...51,320,874
Ensembl chr 7:51,271,754...51,320,867
|
|
G |
Slc17a7 |
solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein |
CTD |
PMID:33713149 |
|
NCBI chr 7:44,813,345...44,825,563
Ensembl chr 7:44,813,373...44,825,566
|
|
G |
Slc22a27 |
solute carrier family 22, member 27 |
multiple interactions |
EXP |
Cyclic AMP inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine] |
CTD |
PMID:20332632 |
|
NCBI chr19:7,841,753...7,943,899
Ensembl chr19:7,841,753...7,943,392
|
|
G |
Slc22a8 |
solute carrier family 22 (organic anion transporter), member 8 |
affects transport |
ISO |
SLC22A8 protein affects the transport of Cyclic AMP |
CTD |
PMID:11306713 |
|
NCBI chr19:8,568,576...8,589,199
Ensembl chr19:8,568,618...8,589,199
|
|
G |
Slc2a5 |
solute carrier family 2 (facilitated glucose transporter), member 5 |
affects expression multiple interactions |
ISO |
Cyclic AMP affects the expression of SLC2A5 mRNA [[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein] which results in increased uptake of Fructose; [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein [Fructose results in increased abundance of Cyclic AMP] which results in increased stability of SLC2A5 mRNA |
CTD |
PMID:8037665 PMID:8554516 PMID:12820898 |
|
NCBI chr 4:150,203,801...150,228,625
Ensembl chr 4:150,203,740...150,228,626
|
|
G |
Slc4a2 |
solute carrier family 4 (anion exchanger), member 2 |
multiple interactions |
ISO |
Nitric Oxide inhibits the reaction [SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates]]; SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates] |
CTD |
PMID:12612912 |
|
NCBI chr 5:24,628,834...24,645,945
Ensembl chr 5:24,628,835...24,645,948
|
|
G |
Smoc2 |
SPARC related modular calcium binding 2 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SMOC2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr17:14,499,768...14,625,052
Ensembl chr17:14,499,768...14,625,052
|
|
G |
Snx33 |
sorting nexin 33 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SNX33 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 9:56,824,472...56,835,726
Ensembl chr 9:56,824,477...56,835,655
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein]; [[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein; dorsomorphin inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein] |
CTD |
PMID:23782265 |
|
NCBI chr11:117,856,905...117,860,192
Ensembl chr11:117,856,905...117,860,873
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
multiple interactions |
ISO |
WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA] |
CTD |
PMID:20685861 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Srd5a1 |
steroid 5 alpha-reductase 1 |
increases expression |
EXP |
Cyclic AMP results in increased expression of SRD5A1 mRNA |
CTD |
PMID:25576683 |
|
NCBI chr13:69,721,568...69,759,611
Ensembl chr13:69,721,568...69,759,561
|
|
G |
Sst |
somatostatin |
multiple interactions |
ISO |
[SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22056254 |
|
NCBI chr16:23,708,327...23,710,041
Ensembl chr16:23,708,323...23,709,708
|
|
G |
Sstr2 |
somatostatin receptor 2 |
multiple interactions |
ISO |
[64Cu-CB-TE2A-Y3-TATE co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22056254 |
|
NCBI chr11:113,510,153...113,516,854
Ensembl chr11:113,510,168...113,516,854
|
|
G |
St6gal2 |
beta galactoside alpha 2,6 sialyltransferase 2 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ST6GAL2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr17:55,752,071...55,821,582
Ensembl chr17:55,752,383...55,821,582
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions increases expression |
EXP |
[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein; Calcium inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]; Diltiazem promotes the reaction [Cyclic AMP results in increased expression of STAR protein]; Isradipine promotes the reaction [Cyclic AMP results in increased expression of STAR protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR mRNA]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]]; myricetin promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; Nifedipine promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR mRNA]; perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR protein] Cyclic AMP results in increased expression of STAR mRNA; Cyclic AMP results in increased expression of STAR protein |
CTD |
PMID:19822634 PMID:20100736 PMID:25576683 PMID:28668616 |
|
NCBI chr 8:26,298,502...26,306,010
Ensembl chr 8:26,296,583...26,306,010
|
|
G |
Taar1 |
trace amine-associated receptor 1 |
multiple interactions |
ISO EXP |
[Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP [3-hydroxy-4-methoxyphenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [3-methoxytyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [3-tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [4-chloro-2-(imidazolin-2-yl)isoindoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [4-phenyl-1,2,3,4-tetrahydroisoquinoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [5-Methoxytryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [6-nitroquipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Antazoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [BE 2254 results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [cirazoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Clonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [efaroxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Fenoldopam results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Guanabenz results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [harman results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Histamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Idazoxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Methoxydimethyltryptamines results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [moxonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [N-methylquipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [O-methyltyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Quipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [rilmenidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tranylcypromine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tryptamines analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:19725810 |
|
NCBI chr10:23,796,304...23,797,302
Ensembl chr10:23,796,254...23,797,367
|
|
G |
Tas1r2 |
taste receptor, type 1, member 2 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TAS1R2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 4:139,380,849...139,397,591
Ensembl chr 4:139,380,849...139,397,591
|
|
G |
Tas2r105 |
taste receptor, type 2, member 105 |
multiple interactions |
EXP |
Pertussis Toxin inhibits the reaction [TAS2R105 protein affects the reaction [Cycloheximide results in decreased abundance of Cyclic AMP]]; TAS2R105 protein affects the reaction [Cycloheximide results in decreased abundance of Cyclic AMP] |
CTD |
PMID:15087236 |
|
NCBI chr 6:131,663,524...131,664,426
Ensembl chr 6:131,663,495...131,664,458
|
|
G |
Tax1bp1 |
Tax1 (human T cell leukemia virus type I) binding protein 1 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TAX1BP1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 6:52,690,677...52,743,765
Ensembl chr 6:52,690,714...52,743,765
|
|
G |
Tdo2 |
tryptophan 2,3-dioxygenase |
multiple interactions |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA |
CTD |
PMID:32781018 |
|
NCBI chr 3:81,865,719...81,883,035
Ensembl chr 3:81,864,397...81,883,509
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA |
CTD |
PMID:33713149 |
|
NCBI chr13:73,775,030...73,797,962
Ensembl chr13:73,775,030...73,797,962
|
|
G |
Tex14 |
testis expressed gene 14 intercellular bridge forming factor |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TEX14 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr11:87,295,839...87,446,649
Ensembl chr11:87,295,891...87,446,649
|
|
G |
Tff1 |
trefoil factor 1 |
multiple interactions increases expression |
ISO |
CARM1 protein promotes the reaction [Cyclic AMP results in increased expression of TFF1 mRNA]; Cyclic AMP promotes the reaction [CARM1 protein binds to TFF1 promoter] |
CTD |
PMID:20360387 |
|
NCBI chr17:31,380,369...31,384,034
Ensembl chr17:31,380,369...31,384,251
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein |
CTD |
PMID:33713149 |
|
NCBI chr12:86,103,517...86,125,815
Ensembl chr12:86,103,519...86,125,815
|
|
G |
Tmsb15b2 |
thymosin beta 15b2 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TMSB15B2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr X:135,855,737...135,858,728
Ensembl chr X:135,856,014...135,858,774
|
|
G |
Tmtc4 |
transmembrane and tetratricopeptide repeat containing 4 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TMTC4 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr14:123,156,383...123,220,697
Ensembl chr14:123,156,383...123,221,447
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO EXP |
Cyclic AMP results in decreased expression of TNF protein Cyclic AMP inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] [[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:8550079 PMID:21266552 PMID:23566200 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfsf12 |
tumor necrosis factor (ligand) superfamily, member 12 |
decreases expression |
EXP |
Cyclic AMP results in decreased expression of TNFSF12 mRNA |
CTD |
PMID:22117073 |
|
NCBI chr11:69,577,066...69,586,924
Ensembl chr11:69,577,076...69,586,675
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
increases expression multiple interactions |
ISO |
Cyclic AMP results in increased expression of TRPV4 mRNA; Cyclic AMP results in increased expression of TRPV4 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of TRPV4 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of TRPV4 protein] |
CTD |
PMID:22187434 |
|
NCBI chr 5:114,760,213...114,796,497
Ensembl chr 5:114,760,213...114,796,482
|
|
G |
Tshb |
thyroid stimulating hormone, beta subunit |
multiple interactions increases abundance |
ISO |
[Cobalt binds to dipyrido(3,2-a-2',3'-c)phenazine binds to N-(2-hydroxybenzyl)glycine analog] inhibits the reaction [TSHB protein results in increased abundance of Cyclic AMP]; [TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP; bisphenol A inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Diethylstilbestrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; resveratrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; TSHB protein inhibits the reaction [NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]] |
CTD |
PMID:19766106 PMID:21072367 PMID:21123444 |
|
NCBI chr 3:102,684,621...102,718,175
Ensembl chr 3:102,682,781...102,690,034
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
multiple interactions increases abundance |
ISO |
[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP; bisphenol A inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Diethylstilbestrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]; resveratrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; TSHB protein inhibits the reaction [NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]] |
CTD |
PMID:19766106 PMID:21123444 |
|
NCBI chr12:91,367,767...91,507,283
Ensembl chr12:91,351,337...91,516,582
|
|
G |
Ttc6 |
tetratricopeptide repeat domain 6 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TTC6 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr12:57,593,490...57,784,697
Ensembl chr12:57,610,899...57,784,714
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein |
CTD |
PMID:33713149 |
|
NCBI chr 8:124,138,292...124,148,754
Ensembl chr 8:124,138,163...124,148,754
|
|
G |
Uba5 |
ubiquitin-like modifier activating enzyme 5 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of UBA5 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 9:103,923,786...103,940,767
Ensembl chr 9:103,923,798...103,940,333
|
|
G |
Vash1 |
vasohibin 1 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VASH1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr12:86,725,474...86,742,462
Ensembl chr12:86,725,474...86,738,865
|
|
G |
Vash2 |
vasohibin 2 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VASH2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:190,679,843...190,711,500
Ensembl chr 1:190,679,843...190,711,493
|
|
G |
Vat1 |
vesicle amine transport 1 |
multiple interactions |
ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VAT1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr11:101,349,574...101,357,025
Ensembl chr11:101,349,571...101,357,056
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
Cyclic AMP affects the reaction [Norepinephrine results in increased expression of VEGFA mRNA] |
CTD |
PMID:10788502 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Vip |
vasoactive intestinal polypeptide |
multiple interactions increases abundance |
ISO |
[VIP protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP alpha-hexachlorocyclohexane inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]; Endrin inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]; Hexachlorocyclohexane inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP] VIP protein results in increased abundance of Cyclic AMP; VIP results in increased abundance of Cyclic AMP |
CTD |
PMID:1657658 PMID:2467674 PMID:7733904 PMID:20732086 |
|
NCBI chr10:5,589,131...5,597,617
Ensembl chr10:5,589,218...5,597,617
|
|
G |
Vipr2 |
vasoactive intestinal peptide receptor 2 |
multiple interactions |
ISO |
[ADCYAP1 protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP; [VIP protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:7733904 |
|
NCBI chr12:116,041,040...116,117,842
Ensembl chr12:116,041,346...116,109,881
|
|
G |
Wnt5a |
wingless-type MMTV integration site family, member 5A |
multiple interactions |
ISO |
WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA]; WNT5A protein affects the reaction [Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] |
CTD |
PMID:20685861 |
|
NCBI chr14:28,224,962...28,249,405
Ensembl chr14:28,226,707...28,249,405
|
|
G |
Zfp36l2 |
zinc finger protein 36, C3H type-like 2 |
increases abundance |
EXP |
ZFP36L2 protein mutant form results in increased abundance of Cyclic AMP |
CTD |
PMID:24830504 |
|
NCBI chr17:84,491,352...84,495,375
Ensembl chr17:84,491,359...84,495,375
|
|
|
G |
Abca1 |
ATP-binding cassette, sub-family A member 1 |
multiple interactions increases expression |
EXP |
Mevalonic Acid inhibits the reaction [mevastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein]]; pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein] |
CTD |
PMID:16415093 |
|
NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
increases expression |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCB11 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
increases expression |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCB1A mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
increases expression |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCC2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
increases expression |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCG2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
increases phosphorylation |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of AKT1 protein |
CTD |
PMID:20610540 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Bcl2l11 |
BCL2 like 11 |
increases expression increases response to substance |
EXP ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 mRNA; 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 protein BCL2L11 protein results in increased susceptibility to 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP |
CTD |
PMID:14996839 |
|
NCBI chr 2:127,967,958...128,004,467
Ensembl chr 2:127,967,958...128,004,467
|
|
G |
Casp3 |
caspase 3 |
increases activity |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased activity of CASP3 protein |
CTD |
PMID:14996839 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cfl1 |
cofilin 1, non-muscle |
decreases phosphorylation |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in decreased phosphorylation of CFL1 protein |
CTD |
PMID:20610540 |
|
NCBI chr19:5,540,483...5,544,059
Ensembl chr19:5,540,483...5,545,229
|
|
G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein mutant form; [5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein mutant form |
CTD |
PMID:15163550 |
|
NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions increases phosphorylation |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of and results in increased activity of CREB1 protein 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of CREB1 protein |
CTD |
PMID:14741741 PMID:20610540 |
|
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
increases expression |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NFE2L2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
multiple interactions |
EXP |
NR1H2 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]] |
CTD |
PMID:16415093 |
|
NCBI chr 7:44,199,040...44,204,928
Ensembl chr 7:44,199,040...44,203,375
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
EXP |
NR1H3 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]] |
CTD |
PMID:16415093 |
|
NCBI chr 2:91,014,406...91,033,189
Ensembl chr 2:91,014,406...91,033,179
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases expression |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NR1I2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases expression |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NR1I3 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 1:171,041,503...171,046,414
Ensembl chr 1:171,041,539...171,048,270
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
multiple interactions |
ISO |
[Acetylcysteine results in increased susceptibility to 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] which results in increased cleavage of PARP1 protein |
CTD |
PMID:38042493 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions decreases activity |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP inhibits the reaction [RHOA protein binds to RTKN protein] 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in decreased activity of RHOA protein |
CTD |
PMID:20610540 |
|
NCBI chr 9:108,183,359...108,215,142
Ensembl chr 9:108,183,328...108,215,133
|
|
G |
Rtkn |
rhotekin |
multiple interactions |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP inhibits the reaction [RHOA protein binds to RTKN protein] |
CTD |
PMID:20610540 |
|
NCBI chr 6:83,112,485...83,129,560
Ensembl chr 6:83,112,444...83,129,560
|
|
G |
Scnn1a |
sodium channel, nonvoltage-gated 1 alpha |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] |
CTD |
PMID:15161604 |
|
NCBI chr 6:125,286,657...125,321,906
Ensembl chr 6:125,297,622...125,321,906
|
|
G |
Scnn1b |
sodium channel, nonvoltage-gated 1 beta |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] |
CTD |
PMID:15161604 |
|
NCBI chr 7:121,464,261...121,517,951
Ensembl chr 7:121,464,261...121,517,737
|
|
G |
Scnn1g |
sodium channel, nonvoltage-gated 1 gamma |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] |
CTD |
PMID:15161604 |
|
NCBI chr 7:121,333,643...121,367,705
Ensembl chr 7:121,333,702...121,367,698
|
|
G |
Slc10a1 |
solute carrier family 10 (sodium/bile acid cotransporter family), member 1 |
increases expression |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLC10A1 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479
|
|
G |
Slco1a1 |
solute carrier organic anion transporter family, member 1a1 |
increases expression |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLCO1A1 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 6:141,853,007...141,892,688
Ensembl chr 6:141,853,008...141,892,688
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
increases expression |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLCO1A4 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 6:141,751,164...141,802,011
Ensembl chr 6:141,751,166...141,801,925
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family, member 1b2 |
increases expression |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLCO1B2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372
|
|
G |
Snap25 |
synaptosomal-associated protein 25 |
multiple interactions affects splicing |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP affects the splicing of SNAP25 exon] |
CTD |
PMID:22684629 |
|
NCBI chr 2:136,555,359...136,624,348
Ensembl chr 2:136,555,373...136,624,348
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP promotes the reaction [Capsaicin results in increased activity of TRPV1] |
CTD |
PMID:12886029 |
|
NCBI chr11:73,124,975...73,152,148
Ensembl chr11:73,125,118...73,152,068
|
|
G |
Vip |
vasoactive intestinal polypeptide |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of VIP mRNA |
CTD |
PMID:2156696 |
|
NCBI chr10:5,589,131...5,597,617
Ensembl chr10:5,589,218...5,597,617
|
|
|
G |
Abca1 |
ATP-binding cassette, sub-family A member 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ABCA1 protein |
CTD |
PMID:17478430 |
|
NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA] |
CTD |
PMID:27743861 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcc1 |
ATP-binding cassette, sub-family C member 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCC1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA] |
CTD |
PMID:27743861 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcd2 |
ATP-binding cassette, sub-family D member 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCD2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:91,029,874...91,076,013
Ensembl chr15:91,030,074...91,076,002
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCG1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:31,276,668...31,336,958
Ensembl chr17:31,276,649...31,336,962
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA] |
CTD |
PMID:30610963 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Ablim1 |
actin-binding LIM protein 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABLIM1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:57,021,165...57,303,776
Ensembl chr19:57,021,165...57,303,351
|
|
G |
Ablim2 |
actin-binding LIM protein 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ABLIM2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:35,915,200...36,042,323
Ensembl chr 5:35,915,224...36,042,317
|
|
G |
Acat2 |
acetyl-Coenzyme A acetyltransferase 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ACAT2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:13,161,929...13,179,612
Ensembl chr17:13,161,777...13,179,634
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ACE2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416
|
|
G |
Acp3 |
acid phosphatase 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ACP3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:104,165,439...104,214,921
Ensembl chr 9:104,165,450...104,214,947
|
|
G |
Adamts6 |
a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADAMTS6 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr13:104,423,026...104,633,203
Ensembl chr13:104,424,343...104,633,203
|
|
G |
Adamts8 |
ADAM metallopeptidase with thrombospondin type 1 motif 8 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADAMTS8 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:30,853,858...30,875,134
Ensembl chr 9:30,853,858...30,875,134
|
|
G |
Adcy7 |
adenylate cyclase 7 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADCY7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:88,998,818...89,056,593
Ensembl chr 8:88,999,031...89,056,590
|
|
G |
Adgrd1 |
adhesion G protein-coupled receptor D1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADGRD1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:129,173,741...129,281,663
Ensembl chr 5:129,173,814...129,281,663
|
|
G |
Adgrf5 |
adhesion G protein-coupled receptor F5 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADGRF5 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr17:43,671,225...43,770,448
Ensembl chr17:43,671,342...43,770,448
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADGRG1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:95,701,321...95,740,836
Ensembl chr 8:95,701,379...95,740,845
|
|
G |
Adgrg2 |
adhesion G protein-coupled receptor G2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADGRG2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:159,173,315...159,281,072
Ensembl chr X:159,173,686...159,281,066
|
|
G |
Adra2a |
adrenergic receptor, alpha 2a |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADRA2A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:54,033,690...54,037,413
Ensembl chr19:54,032,582...54,037,413
|
|
G |
Agr2 |
anterior gradient 2 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of AGR2 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr12:36,042,924...36,054,080
Ensembl chr12:36,042,906...36,054,086
|
|
G |
Agt |
angiotensinogen |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AGT mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AGTR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AHR mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037
|
|
G |
Aifm1 |
apoptosis-inducing factor, mitochondrion-associated 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AIFM1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:47,563,821...47,602,440
Ensembl chr X:47,563,821...47,602,440
|
|
G |
Akap7 |
A kinase anchor protein 7 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of AKAP7 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr10:25,044,988...25,175,115
Ensembl chr10:25,044,988...25,183,768
|
|
G |
Akap9 |
A kinase anchor protein 9 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AKAP9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:3,977,410...4,130,204
Ensembl chr 5:3,978,054...4,131,310
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AKT1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Alb |
albumin |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ALB mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase family 1, subfamily A1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ALDH1A1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:20,469,947...20,620,827
Ensembl chr19:20,470,079...20,620,829
|
|
G |
Angpt1 |
angiopoietin 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ANGPT1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr15:42,288,063...42,540,373
Ensembl chr15:42,288,119...42,540,373
|
|
G |
Angptl1 |
angiopoietin-like 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ANGPTL1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:156,666,495...156,688,648
Ensembl chr 1:156,666,132...156,688,648
|
|
G |
Ank |
progressive ankylosis |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ANKH mRNA |
CTD |
PMID:20147733 |
|
NCBI chr15:27,466,763...27,594,995
Ensembl chr15:27,466,763...27,594,995
|
|
G |
Anxa8 |
annexin A8 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of ANXA8 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr14:33,807,936...33,822,528
Ensembl chr14:33,807,938...33,822,528
|
|
G |
Aopep |
aminopeptidase O |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AOPEP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:63,112,707...63,473,910
Ensembl chr13:63,112,707...63,473,910
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APAF1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:90,825,173...90,918,688
Ensembl chr10:90,825,173...90,918,632
|
|
G |
Apbb1ip |
amyloid beta precursor protein binding family B member 1 interacting protein |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of APBB1IP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:22,645,983...22,765,671
Ensembl chr 2:22,664,106...22,765,665
|
|
G |
Apc |
APC, WNT signaling pathway regulator |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APC mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:34,353,350...34,455,243
Ensembl chr18:34,353,977...34,455,605
|
|
G |
Apcdd1 |
adenomatosis polyposis coli down-regulated 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APCDD1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:63,055,398...63,086,886
Ensembl chr18:63,055,302...63,094,250
|
|
G |
Ar |
androgen receptor |
decreases expression multiple interactions |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AR mRNA [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA] |
CTD |
PMID:18467523 PMID:22079614 |
|
NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821
|
|
G |
Areg |
amphiregulin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AREG mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr 5:91,287,458...91,296,291
Ensembl chr 5:91,287,458...91,296,291
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ARHGEF2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:88,500,427...88,556,839
Ensembl chr 3:88,513,273...88,555,359
|
|
G |
Arhgef4 |
Rho guanine nucleotide exchange factor 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARHGEF4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:34,717,263...34,851,819
Ensembl chr 1:34,717,269...34,852,390
|
|
G |
Arid5b |
AT-rich interaction domain 5B |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ARID5B mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:67,928,353...68,114,596
Ensembl chr10:67,928,350...68,114,570
|
|
G |
Armcx3 |
armadillo repeat containing, X-linked 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARMCX3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:133,657,301...133,662,206
Ensembl chr X:133,657,344...133,662,204
|
|
G |
Armcx4 |
armadillo repeat containing, X-linked 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARMCX4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:133,586,399...133,598,524
Ensembl chr X:133,587,268...133,597,506
|
|
G |
Asns |
asparagine synthetase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ASNS mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:7,675,169...7,693,209
Ensembl chr 6:7,675,169...7,693,254
|
|
G |
Atp4a |
ATPase, H+/K+ exchanging, gastric, alpha polypeptide |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ATP4A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:30,411,634...30,424,959
Ensembl chr 7:30,411,634...30,424,959
|
|
G |
Avpi1 |
arginine vasopressin-induced 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AVPI1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:42,111,714...42,117,432
Ensembl chr19:42,111,712...42,117,498
|
|
G |
B4galnt3 |
beta-1,4-N-acetyl-galactosaminyl transferase 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of B4GALNT3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:120,177,714...120,271,879
Ensembl chr 6:120,180,034...120,271,520
|
|
G |
Bank1 |
B cell scaffold protein with ankyrin repeats 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BANK1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:135,759,124...136,031,902
Ensembl chr 3:135,759,124...136,031,827
|
|
G |
Bax |
BCL2-associated X protein |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BAX [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BAX protein |
CTD |
PMID:11802967 PMID:16709600 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcat1 |
branched chain aminotransferase 1, cytosolic |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BCAT1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:144,939,561...145,021,883
Ensembl chr 6:144,939,561...145,021,910
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BCL2 |
CTD |
PMID:11802967 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l11 |
BCL2 like 11 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BCL2L11 protein |
CTD |
PMID:16709600 |
|
NCBI chr 2:127,967,958...128,004,467
Ensembl chr 2:127,967,958...128,004,467
|
|
G |
Bdkrb1 |
bradykinin receptor, beta 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BDKRB1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr12:105,570,350...105,571,770
Ensembl chr12:105,569,344...105,571,687
|
|
G |
Bdkrb2 |
bradykinin receptor, beta 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BDKRB2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr12:105,529,431...105,561,503
Ensembl chr12:105,529,485...105,561,496
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BMP4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:46,620,982...46,628,126
Ensembl chr14:46,620,977...46,628,126
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
decreases expression increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BMP6 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BMP6 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr13:38,529,098...38,684,283
Ensembl chr13:38,529,083...38,684,278
|
|
G |
Brinp1 |
bone morphogenic protein/retinoic acid inducible neural specific 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BRINP1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 4:68,679,609...68,872,634
Ensembl chr 4:68,679,751...68,872,634
|
|
G |
Btbd9 |
BTB domain containing 9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BTBD9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:30,434,498...30,801,595
Ensembl chr17:30,434,498...30,795,462
|
|
G |
Cables1 |
CDK5 and Abl enzyme substrate 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CABLES1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:11,972,600...12,078,681
Ensembl chr18:11,972,277...12,078,687
|
|
G |
Cabp7 |
calcium binding protein 7 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CABP7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:4,686,892...4,697,179
Ensembl chr11:4,686,892...4,696,778
|
|
G |
Cadm1 |
cell adhesion molecule 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CADM1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:47,441,468...47,773,578
Ensembl chr 9:47,441,471...47,769,413
|
|
G |
Cadm2 |
cell adhesion molecule 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CADM2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:66,452,302...67,417,825
Ensembl chr16:66,452,307...67,417,796
|
|
G |
Caln1 |
calneuron 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CALN1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:130,398,245...130,876,253
Ensembl chr 5:130,398,296...130,876,253
|
|
G |
Calr |
calreticulin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CALR mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563
|
|
G |
Camk2n1 |
calcium/calmodulin-dependent protein kinase II inhibitor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAMK2N1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:138,182,459...138,187,437
Ensembl chr 4:138,181,625...138,187,434
|
|
G |
Capn15 |
calpain 15 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CAPN15 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:26,177,338...26,204,753
Ensembl chr17:26,177,338...26,204,770
|
|
G |
Capn2 |
calpain 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAPN2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:182,294,818...182,345,175
Ensembl chr 1:182,294,825...182,345,173
|
|
G |
Capn6 |
calpain 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAPN6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:142,585,232...142,610,408
Ensembl chr X:142,585,227...142,610,410
|
|
G |
Card14 |
caspase recruitment domain family, member 14 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CARD14 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:119,197,923...119,236,205
Ensembl chr11:119,198,594...119,236,201
|
|
G |
Cars1 |
cysteinyl-tRNA synthetase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CARS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:143,110,967...143,153,827
Ensembl chr 7:143,110,967...143,153,827
|
|
G |
Casp3 |
caspase 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CASP3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CASP9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CAT mRNA |
CTD |
PMID:16709600 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cbr4 |
carbonyl reductase 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CBR4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:61,940,768...61,956,534
Ensembl chr 8:61,940,768...61,959,728
|
|
G |
Ccdc170 |
coiled-coil domain containing 170 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCDC170 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:4,432,312...4,514,498
Ensembl chr10:4,432,502...4,512,231
|
|
G |
Ccdc3 |
coiled-coil domain containing 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCDC3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:5,142,587...5,235,682
Ensembl chr 2:5,142,587...5,235,689
|
|
G |
Ccdc80 |
coiled-coil domain containing 80 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCDC80 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:44,913,770...44,948,287
Ensembl chr16:44,913,765...44,948,440
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein]]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]]; [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of CCL2 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCL2 protein |
CTD |
PMID:11230753 PMID:16997883 PMID:20940016 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Reactive Oxygen Species results in increased expression of CCL5 mRNA]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA] |
CTD |
PMID:10495789 |
|
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Ccn3 |
cellular communication network factor 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCN3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:54,609,306...54,617,158
Ensembl chr15:54,609,098...54,617,435
|
|
G |
Ccn6 |
cellular communication network factor 6 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCN6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:39,026,966...39,049,484
Ensembl chr10:39,026,966...39,039,790
|
|
G |
Ccna1 |
cyclin A1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCNA1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:54,952,890...54,965,055
Ensembl chr 3:54,952,890...54,962,922
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCND2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:127,102,125...127,131,913
Ensembl chr 6:127,102,125...127,129,156
|
|
G |
Cd244a |
CD244 molecule A |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD244 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:171,386,761...171,412,884
Ensembl chr 1:171,386,761...171,437,314
|
|
G |
Cd74 |
CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated) |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD74 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:60,936,921...60,945,724
Ensembl chr18:60,936,920...60,945,724
|
|
G |
Cd9 |
CD9 antigen |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:125,437,229...125,471,723
Ensembl chr 6:125,437,229...125,471,754
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH1 protein |
CTD |
PMID:32028606 |
|
NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878
|
|
G |
Cdh22 |
cadherin 22 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH22 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:164,953,421...165,076,892
Ensembl chr 2:164,953,427...165,076,773
|
|
G |
Cdh4 |
cadherin 4 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:179,084,228...179,541,166
Ensembl chr 2:179,084,224...179,541,166
|
|
G |
Cdh6 |
cadherin 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CDH6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:13,028,785...13,176,493
Ensembl chr15:13,028,787...13,173,761
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDK2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDKN1A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdon |
cell adhesion molecule-related/down-regulated by oncogenes |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CDON mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 9:35,332,836...35,418,948
Ensembl chr 9:35,332,424...35,418,948
|
|
G |
Cdx1 |
caudal type homeobox 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDX1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:61,151,934...61,169,292
Ensembl chr18:61,151,934...61,169,271
|
|
G |
Cebpg |
CCAAT/enhancer binding protein gamma |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CEBPG mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:34,745,847...34,755,991
Ensembl chr 7:34,745,847...34,755,998
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CFLAR protein alternative form |
CTD |
PMID:16709600 |
|
NCBI chr 1:58,750,353...58,798,043
Ensembl chr 1:58,750,667...58,798,043
|
|
G |
Cga |
glycoprotein hormones, alpha subunit |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CGA mRNA |
CTD |
PMID:8404651 PMID:21467749 PMID:22079614 |
|
NCBI chr 4:34,893,779...34,907,374
Ensembl chr 4:34,893,779...34,907,370
|
|
G |
Cgn |
cingulin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CGN mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:94,667,376...94,695,036
Ensembl chr 3:94,667,376...94,693,826
|
|
G |
Chn1 |
chimerin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CHN1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:73,441,004...73,605,723
Ensembl chr 2:73,441,004...73,605,690
|
|
G |
Chp1 |
calcineurin-like EF hand protein 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CHP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:119,378,172...119,417,505
Ensembl chr 2:119,378,178...119,417,508
|
|
G |
Cidea |
cell death-inducing DNA fragmentation factor, alpha subunit-like effector A |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CIDEA mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:67,476,634...67,500,864
Ensembl chr18:67,476,674...67,500,855
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
increases expression |
EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CIDEC protein |
CTD |
PMID:21097823 |
|
NCBI chr 6:113,401,595...113,412,721
Ensembl chr 6:113,401,595...113,412,721
|
|
G |
Ckmt2 |
creatine kinase, mitochondrial 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CKMT2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:92,001,510...92,025,001
Ensembl chr13:92,001,506...92,025,004
|
|
G |
Cldn1 |
claudin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CLDN1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:26,175,395...26,190,589
Ensembl chr16:26,175,392...26,190,591
|
|
G |
Cldn5 |
claudin 5 |
increases expression |
EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLDN5 mRNA |
CTD |
PMID:20711499 |
|
NCBI chr16:18,595,597...18,597,012
Ensembl chr16:18,595,597...18,597,012
|
|
G |
Clgn |
calmegin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLGN mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr 8:84,116,454...84,155,181
Ensembl chr 8:84,116,496...84,155,181
|
|
G |
Clic3 |
chloride intracellular channel 3 |
multiple interactions increases expression |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CLIC3 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLIC3 mRNA |
CTD |
PMID:16997883 PMID:22079614 |
|
NCBI chr 2:25,346,855...25,348,789
Ensembl chr 2:25,346,850...25,348,788
|
|
G |
Cmklr1 |
chemerin chemokine-like receptor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CMKLR1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 5:113,750,415...113,792,971
Ensembl chr 5:113,750,415...113,788,487
|
|
G |
Cnih3 |
cornichon family AMPA receptor auxiliary protein 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CNIH3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:181,178,024...181,288,059
Ensembl chr 1:181,180,193...181,288,206
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CNR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:33,923,171...33,948,831
Ensembl chr 4:33,924,593...33,948,831
|
|
G |
Col15a1 |
collagen, type XV, alpha 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL15A1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 4:47,207,744...47,313,165
Ensembl chr 4:47,208,161...47,313,167
|
|
G |
Col4a4 |
collagen, type IV, alpha 4 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of COL4A4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:82,426,140...82,564,570
Ensembl chr 1:82,426,144...82,564,570
|
|
G |
Col4a6 |
collagen, type IV, alpha 6 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL4A6 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr X:139,948,399...140,257,091
Ensembl chr X:139,948,399...140,257,072
|
|
G |
Col6a3 |
collagen, type VI, alpha 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of COL6A3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:90,694,582...90,771,710
Ensembl chr 1:90,693,645...90,771,693
|
|
G |
Col7a1 |
collagen, type VII, alpha 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL7A1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 9:108,782,654...108,813,943
Ensembl chr 9:108,782,654...108,813,943
|
|
G |
Colec12 |
collectin sub-family member 12 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of COLEC12 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:9,707,648...9,877,995
Ensembl chr18:9,707,595...9,882,644
|
|
G |
Coro2a |
coronin, actin binding protein 2A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CORO2A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:46,536,937...46,601,929
Ensembl chr 4:46,536,937...46,602,202
|
|
G |
Cpm |
carboxypeptidase M |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CPM mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:117,465,405...117,523,257
Ensembl chr10:117,465,405...117,523,257
|
|
G |
Cradd |
CASP2 and RIPK1 domain containing adaptor with death domain |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CRADD mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:95,010,601...95,160,000
Ensembl chr10:95,010,608...95,159,995
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of CREB1 protein |
CTD |
PMID:18467523 |
|
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Testosterone]] |
CTD |
PMID:2153673 |
|
NCBI chr 3:19,747,565...19,749,560
Ensembl chr 3:19,747,565...19,749,560
|
|
G |
Crhbp |
corticotropin releasing hormone binding protein |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CRHBP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:95,567,884...95,581,339
Ensembl chr13:95,567,879...95,581,432
|
|
G |
Cst6 |
cystatin E/M |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of CST6 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr19:5,394,733...5,399,602
Ensembl chr19:5,394,733...5,399,602
|
|
G |
Ctnna2 |
catenin alpha 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CTNNA2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:76,858,620...77,956,798
Ensembl chr 6:76,858,620...77,956,682
|
|
G |
Cttnbp2 |
cortactin binding protein 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CTTNBP2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:18,366,470...18,515,216
Ensembl chr 6:18,366,477...18,514,842
|
|
G |
Cux2 |
cut-like homeobox 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CUX2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:121,996,025...122,188,522
Ensembl chr 5:121,994,429...122,188,165
|
|
G |
Cx3cl1 |
C-X3-C motif chemokine ligand 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CX3CL1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:95,498,808...95,509,055
Ensembl chr 8:95,498,637...95,509,055
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CXCL10 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression increases expression |
EXP ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CXCL12 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CXCL12 mRNA |
CTD |
PMID:20711499 PMID:22079614 |
|
NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions increases expression |
ISO |
daidzein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CXCL8 mRNA]; Estradiol inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CXCL8 mRNA]; Genistein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CXCL8 mRNA] |
CTD |
PMID:21056929 PMID:22079614 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cycs |
cytochrome c, somatic |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYCS mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions increases expression increases activity |
EXP ISO |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]]; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; Hydrocarbons, Chlorinated inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP11A1 protein 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP11A1 protein] |
CTD |
PMID:20147733 PMID:21126571 PMID:21610156 PMID:21664964 PMID:21726595 PMID:22546480 PMID:24014645 PMID:24328340 PMID:24740604 PMID:34896276 More...
|
|
NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
increases expression multiple interactions |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11B2 mRNA [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11B1 mRNA |
CTD |
PMID:21610156 PMID:22079614 PMID:34896276 |
|
NCBI chr15:74,722,467...74,728,080
Ensembl chr15:74,722,859...74,728,167
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO EXP |
[4-nitro-3-phenylphenol co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of CYP17A1 protein; bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]]; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP17A1 mRNA; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein] |
CTD |
PMID:18336853 PMID:21610156 PMID:21726595 PMID:22079614 PMID:22546480 PMID:24014645 PMID:34896276 More...
|
|
NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions increases expression increases activity |
ISO EXP |
[vinclozolin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP19A1 mRNA; Atrazine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; Atrazine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 mRNA]; bisphenol A inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; formestane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; Methoxychlor inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein] [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP19A1 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 protein |
CTD |
PMID:10746939 PMID:18815356 PMID:21126571 PMID:21610156 PMID:22120136 PMID:23583632 PMID:28859905 PMID:30951242 More...
|
|
NCBI chr 9:54,073,221...54,175,448
Ensembl chr 9:54,073,221...54,175,394
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 protein |
CTD |
PMID:7588239 PMID:22079614 |
|
NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490
|
|
G |
Cyp21a1 |
cytochrome P450, family 21, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP21A2 mRNA [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP21A1 mRNA bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP21A2 mRNA]; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP21A2 mRNA] |
CTD |
PMID:21610156 PMID:22079614 PMID:22546480 PMID:34896276 |
|
NCBI chr17:35,020,322...35,023,400
Ensembl chr17:35,020,322...35,023,535
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:74,752,311...74,777,056
Ensembl chr 1:74,752,733...74,777,051
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP2E1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
|
|
G |
Cyp2f2 |
cytochrome P450, family 2, subfamily f, polypeptide 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP2F1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:26,819,380...26,833,085
Ensembl chr 7:26,819,334...26,833,085
|
|
G |
Cyp3a13 |
cytochrome P450, family 3, subfamily a, polypeptide 13 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP3A5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression multiple interactions |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP51A1 mRNA [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 mRNA; [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 protein; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 mRNA]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 protein] |
CTD |
PMID:18467523 PMID:22079614 |
|
NCBI chr 5:4,130,674...4,154,697
Ensembl chr 5:4,131,145...4,154,746
|
|
G |
Cyp8b1 |
cytochrome P450, family 8, subfamily b, polypeptide 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP8B1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:121,743,422...121,745,371
Ensembl chr 9:121,743,422...121,745,371
|
|
G |
Cyth1 |
cytohesin 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYTH1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:118,054,996...118,139,452
Ensembl chr11:118,022,845...118,139,386
|
|
G |
Dach2 |
dachshund family transcription factor 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DACH2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:112,207,177...112,746,083
Ensembl chr X:112,207,207...112,746,083
|
|
G |
Dact1 |
dishevelled-binding antagonist of beta-catenin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DACT1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:71,356,658...71,366,881
Ensembl chr12:71,356,658...71,366,881
|
|
G |
Dbil5 |
diazepam binding inhibitor-like 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DBIL5P mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:76,108,439...76,109,491
Ensembl chr11:76,108,434...76,109,492
|
|
G |
Dcaf12l1 |
DDB1 and CUL4 associated factor 12-like 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DCAF12L1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:43,875,444...43,879,074
Ensembl chr X:43,875,447...43,879,074
|
|
G |
Dcbld2 |
discoidin, CUB and LCCL domain containing 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DCBLD2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:58,228,789...58,304,013
Ensembl chr16:58,228,806...58,290,090
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DGAT2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:98,802,870...98,831,920
Ensembl chr 7:98,802,865...98,831,926
|
|
G |
Dgkb |
diacylglycerol kinase, beta |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DGKB mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:37,930,169...38,684,238
Ensembl chr12:37,867,725...38,684,238
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DHCR24 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:106,418,279...106,446,310
Ensembl chr 4:106,418,235...106,446,310
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DHCR7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:143,376,827...143,402,147
Ensembl chr 7:143,376,882...143,402,147
|
|
G |
Dhrs2 |
dehydrogenase/reductase member 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DHRS2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:55,459,464...55,478,897
Ensembl chr14:55,459,464...55,478,892
|
|
G |
Dhrs3 |
dehydrogenase/reductase 3 |
multiple interactions |
ISO |
7-propyl spirolactone inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein]; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein; Aldosterone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA] |
CTD |
PMID:23275455 |
|
NCBI chr 4:144,618,712...144,654,214
Ensembl chr 4:144,619,397...144,654,779
|
|
G |
Dio2 |
deiodinase, iodothyronine, type II |
multiple interactions increases activity |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of and results in increased activity of DIO2 protein 8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein Acetylcysteine inhibits the reaction [Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]]; Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]; Sodium Selenite inhibits the reaction [Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]] |
CTD |
PMID:11425850 PMID:18420745 |
|
NCBI chr12:90,691,326...90,705,812
Ensembl chr12:90,691,326...90,705,812
|
|
G |
Dio3 |
deiodinase, iodothyronine type III |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [[Hydrogen Peroxide co-treated with Sodium Selenite] promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein]]; Acetylcysteine inhibits the reaction [Hydrogen Peroxide promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein]]; Hydrogen Peroxide promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein] |
CTD |
PMID:18420745 |
|
NCBI chr12:110,245,664...110,247,531
Ensembl chr12:110,245,502...110,247,531
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DKK1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:30,523,276...30,526,896
Ensembl chr19:30,523,263...30,527,065
|
|
G |
Dnah5 |
dynein, axonemal, heavy chain 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNAH5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:28,155,000...28,472,191
Ensembl chr15:28,203,898...28,472,198
|
|
G |
Dnajb3 |
DnaJ heat shock protein family (Hsp40) member B3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DNAJB3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:88,132,454...88,133,470
Ensembl chr 1:88,132,454...88,133,504
|
|
G |
Dnajb7 |
DnaJ heat shock protein family (Hsp40) member B7 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNAJB7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:81,291,289...81,292,474
Ensembl chr15:81,291,127...81,292,500
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNAJB9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:44,252,680...44,256,851
Ensembl chr12:44,252,342...44,257,109
|
|
G |
Dner |
delta/notch-like EGF repeat containing |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNER mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:84,347,560...84,673,942
Ensembl chr 1:84,347,560...84,673,942
|
|
G |
Dock11 |
dedicator of cytokinesis 11 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DOCK11 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:35,150,924...35,340,223
Ensembl chr X:35,152,485...35,340,215
|
|
G |
Dok5 |
docking protein 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DOK5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:170,573,722...170,721,695
Ensembl chr 2:170,573,727...170,721,689
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DUSP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102
|
|
G |
Dusp16 |
dual specificity phosphatase 16 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DUSP16 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:134,692,431...134,769,687
Ensembl chr 6:134,692,431...134,769,588
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DUSP4 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 8:35,274,448...35,289,106
Ensembl chr 8:35,274,451...35,287,048
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DUSP6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:99,098,676...99,103,351
Ensembl chr10:99,099,093...99,103,351
|
|
G |
Ebp |
EBP cholestenol delta-isomerase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EBP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:8,051,568...8,059,751
Ensembl chr X:8,051,568...8,059,751
|
|
G |
Echs1 |
enoyl Coenzyme A hydratase, short chain, 1, mitochondrial |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ECHS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:139,685,623...139,696,334
Ensembl chr 7:139,685,623...139,696,389
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
EXP |
EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]] |
CTD |
PMID:18467523 |
|
NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965
|
|
G |
Egfr |
epidermal growth factor receptor |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGFR mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Egr2 |
early growth response 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGR2 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr10:67,370,334...67,383,354
Ensembl chr10:67,371,305...67,378,018
|
|
G |
Elp1 |
elongator complex protein 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ELP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:56,746,547...56,802,565
Ensembl chr 4:56,749,680...56,802,331
|
|
G |
Emp2 |
epithelial membrane protein 2 |
multiple interactions decreases expression |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of EMP2 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EMP2 mRNA |
CTD |
PMID:16997883 PMID:22079614 |
|
NCBI chr16:10,099,613...10,131,832
Ensembl chr16:10,099,613...10,131,832
|
|
G |
Enox1 |
ecto-NOX disulfide-thiol exchanger 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ENOX1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr14:77,393,790...77,959,203
Ensembl chr14:77,394,203...77,959,200
|
|
G |
Ep300 |
E1A binding protein p300 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EP300 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:81,470,329...81,536,273
Ensembl chr15:81,469,552...81,536,278
|
|
G |
Epg5 |
ectopic P-granules 5 autophagy tethering factor |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EPG5 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr18:77,981,618...78,080,539
Ensembl chr18:77,981,680...78,078,228
|
|
G |
Ephx1 |
epoxide hydrolase 1, microsomal |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EPHX1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:180,817,121...180,845,134
Ensembl chr 1:180,803,775...180,848,469
|
|
G |
Erap1 |
endoplasmic reticulum aminopeptidase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ERAP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:74,787,692...74,841,321
Ensembl chr13:74,787,687...74,841,320
|
|
G |
Erf |
Ets2 repressor factor |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ERF mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:24,941,985...24,950,522
Ensembl chr 7:24,941,986...24,950,186
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ESR2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
Esrra |
estrogen related receptor, alpha |
increases expression |
EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ESRRA mRNA |
CTD |
PMID:23166782 |
|
NCBI chr19:6,888,345...6,899,182
Ensembl chr19:6,888,345...6,899,208
|
|
G |
Esrrg |
estrogen-related receptor gamma |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ESRRG mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:187,340,707...187,947,082
Ensembl chr 1:187,340,988...187,947,082
|
|
G |
Etnppl |
ethanolamine phosphate phospholyase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ETNPPL mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:130,411,097...130,429,399
Ensembl chr 3:130,411,097...130,431,170
|
|
G |
Etv1 |
ets variant 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ETV1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr12:38,829,655...38,920,484
Ensembl chr12:38,829,379...38,920,483
|
|
G |
Etv5 |
ets variant 5 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ETV5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:22,200,063...22,258,320
Ensembl chr16:22,200,059...22,258,469
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
decreases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EZH2 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EZH2 protein [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in decreased expression of EZH2 mRNA; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in decreased expression of EZH2 protein; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA] |
CTD |
PMID:21903722 |
|
NCBI chr 6:47,507,208...47,613,843
Ensembl chr 6:47,507,073...47,572,275
|
|
G |
F2rl2 |
coagulation factor II thrombin receptor like 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of F2RL2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr13:95,833,428...95,839,276
Ensembl chr13:95,833,361...95,839,247
|
|
G |
Fabp1 |
fatty acid binding protein 1, liver |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FABP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:71,176,863...71,182,018
Ensembl chr 6:71,176,811...71,182,007
|
|
G |
Fads1 |
fatty acid desaturase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FADS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:10,160,245...10,174,238
Ensembl chr19:10,160,252...10,174,241
|
|
G |
Fasl |
Fas ligand |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FASLG protein |
CTD |
PMID:16709600 |
|
NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064
|
|
G |
Fbln1 |
fibulin 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FBLN1 mRNA |
CTD |
PMID:15774544 |
|
NCBI chr15:85,090,150...85,170,495
Ensembl chr15:85,090,150...85,170,736
|
|
G |
Fbxo32 |
F-box protein 32 |
multiple interactions |
ISO |
[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA] |
CTD |
PMID:23275455 |
|
NCBI chr15:58,039,275...58,078,288
Ensembl chr15:58,039,275...58,078,328
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDFT1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:63,382,599...63,419,136
Ensembl chr14:63,382,599...63,417,027
|
|
G |
Fdx1 |
ferredoxin 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDX1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:51,854,323...51,874,902
Ensembl chr 9:51,854,606...51,874,856
|
|
G |
Fdxr |
ferredoxin reductase |
increases expression multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDXR protein Hydrocarbons, Chlorinated inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDXR protein] |
CTD |
PMID:24740604 |
|
NCBI chr11:115,158,850...115,167,925
Ensembl chr11:115,158,850...115,167,876
|
|
G |
Fer1l6 |
fer-1 like family member 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FER1L6 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr15:58,381,897...58,536,936
Ensembl chr15:58,381,897...58,536,941
|
|
G |
Fgf10 |
fibroblast growth factor 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FGF10 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr13:118,851,199...118,928,651
Ensembl chr13:118,806,327...118,928,651
|
|
G |
Fgf13 |
fibroblast growth factor 13 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FGF13 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:58,107,499...58,630,932
Ensembl chr X:58,107,505...58,613,431
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FGF9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:58,308,543...58,350,311
Ensembl chr14:58,308,004...58,350,177
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FHL2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:43,162,233...43,237,501
Ensembl chr 1:43,162,234...43,236,144
|
|
G |
Flot1 |
flotillin 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FLOT1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr17:36,134,243...36,143,674
Ensembl chr17:36,134,122...36,143,683
|
|
G |
Flot2 |
flotillin 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FLOT2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:77,928,757...77,951,260
Ensembl chr11:77,928,757...77,951,260
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FN1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 protein; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of PRL protein]; Hydrogen Peroxide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 mRNA]; Hydrogen Peroxide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 protein] |
CTD |
PMID:16709600 |
|
NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] inhibits the reaction [Hydrogen Peroxide results in increased expression of FOXO3 mRNA]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] inhibits the reaction [Hydrogen Peroxide results in increased expression of FOXO3 protein]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA] |
CTD |
PMID:16709600 |
|
NCBI chr10:42,057,841...42,152,691
Ensembl chr10:42,057,837...42,152,751
|
|
G |
Foxr1 |
forkhead box R1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FOXR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:44,345,531...44,352,165
Ensembl chr 9:44,345,070...44,352,433
|
|
G |
Fras1 |
Fraser extracellular matrix complex subunit 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FRAS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:96,518,622...96,932,592
Ensembl chr 5:96,521,814...96,932,587
|
|
G |
Fshb |
follicle stimulating hormone beta |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FSHB mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FSHB protein Tetrachlorodibenzodioxin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FSHB mRNA] |
CTD |
PMID:8404651 PMID:10746652 PMID:21467749 |
|
NCBI chr 2:106,886,331...106,889,996
Ensembl chr 2:106,886,485...106,890,001
|
|
G |
Fzd10 |
frizzled class receptor 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FZD10 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:128,678,170...128,681,157
Ensembl chr 5:128,677,908...128,681,157
|
|
G |
Fzd4 |
frizzled class receptor 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FZD4 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr 7:89,053,574...89,062,341
Ensembl chr 7:89,053,563...89,062,342
|
|
G |
Fzd7 |
frizzled class receptor 7 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FZD7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:59,521,306...59,526,114
Ensembl chr 1:59,521,583...59,526,114
|
|
G |
Gabbr2 |
gamma-aminobutyric acid type B receptor subunit 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GABBR2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:46,662,318...46,991,714
Ensembl chr 4:46,662,305...46,991,873
|
|
G |
Gabra4 |
gamma-aminobutyric acid type A receptor subunit alpha 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GABRA4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:71,727,077...71,815,651
Ensembl chr 5:71,727,092...71,815,651
|
|
G |
Gabrg1 |
gamma-aminobutyric acid type A receptor subunit gamma 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GABRG1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:70,906,512...70,999,960
Ensembl chr 5:70,908,390...70,999,960
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible 45 alpha |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of GADD45A mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of GADD45A protein |
CTD |
PMID:16709600 |
|
NCBI chr 6:67,012,080...67,014,391
Ensembl chr 6:67,012,080...67,014,441
|
|
G |
Galnt12 |
polypeptide N-acetylgalactosaminyltransferase 12 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GALNT12 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 4:47,091,894...47,123,058
Ensembl chr 4:47,091,909...47,123,070
|
|
G |
Galr1 |
galanin receptor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GALR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:82,410,621...82,424,902
Ensembl chr18:82,410,505...82,424,902
|
|
G |
Gap43 |
growth associated protein 43 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GAP43 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr16:42,068,915...42,161,014
Ensembl chr16:42,068,805...42,161,014
|
|
G |
Gck |
glucokinase |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GCK mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:5,850,816...5,900,081
Ensembl chr11:5,850,820...5,900,081
|
|
G |
Gcsam |
germinal center associated, signaling and motility |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GCSAM mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:45,430,803...45,443,230
Ensembl chr16:45,430,743...45,443,230
|
|
G |
Gdf10 |
growth differentiation factor 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GDF10 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:33,645,544...33,658,471
Ensembl chr14:33,645,544...33,659,940
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GDF15 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:71,082,043...71,085,106
Ensembl chr 8:71,082,043...71,085,106
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GFAP mRNA 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [ochratoxin A results in decreased expression of GFAP mRNA] |
CTD |
PMID:15994020 |
|
NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738
|
|
G |
Gfpt2 |
glutamine fructose-6-phosphate transaminase 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GFPT2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr11:49,684,981...49,729,448
Ensembl chr11:49,685,005...49,729,440
|
|
G |
Gimap8 |
GTPase, IMAP family member 8 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GIMAP8 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:48,624,120...48,637,809
Ensembl chr 6:48,624,168...48,637,809
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GJA1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GJB2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:57,336,059...57,342,159
Ensembl chr14:57,336,057...57,342,159
|
|
G |
Gk |
glycerol kinase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GK mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:84,745,543...84,820,425
Ensembl chr X:84,745,543...84,820,425
|
|
G |
Glipr1 |
GLI pathogenesis related 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GLIPR1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr10:111,821,353...111,838,539
Ensembl chr10:111,821,353...111,838,536
|
|
G |
Glrx |
glutaredoxin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GLRX mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:75,988,004...75,998,270
Ensembl chr13:75,987,987...75,998,273
|
|
G |
Gm13754 |
predicted gene 13754 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CPO mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:63,957,040...63,973,947
Ensembl chr 1:63,957,007...63,975,091
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI2 protein] |
CTD |
PMID:19252090 |
|
NCBI chr 9:107,491,324...107,512,542
Ensembl chr 9:107,491,324...107,512,566
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI3 protein] |
CTD |
PMID:19252090 |
|
NCBI chr 3:108,014,591...108,053,468
Ensembl chr 3:108,014,596...108,053,462
|
|
G |
Gng2 |
guanine nucleotide binding protein (G protein), gamma 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GNG2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:19,922,626...20,027,893
Ensembl chr14:19,922,627...20,027,695
|
|
G |
Gpr22 |
G protein-coupled receptor 22 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GPR22 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:31,756,866...31,763,882
Ensembl chr12:31,756,866...31,763,946
|
|
G |
Gpr37 |
G protein-coupled receptor 37 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GPR37 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:25,668,522...25,689,979
Ensembl chr 6:25,665,877...25,690,728
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GPX1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Grb10 |
growth factor receptor bound protein 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GRB10 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:11,880,499...11,987,428
Ensembl chr11:11,880,508...11,988,683
|
|
G |
Grb14 |
growth factor receptor bound protein 14 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GRB14 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:64,742,820...64,853,143
Ensembl chr 2:64,742,820...64,855,331
|
|
G |
Grem2 |
gremlin 2, DAN family BMP antagonist |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GREM2 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr 1:174,661,352...174,749,386
Ensembl chr 1:174,661,351...174,749,385
|
|
G |
Gria1 |
glutamate receptor, ionotropic, AMPA1 (alpha 1) |
multiple interactions |
ISO |
[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA; NR3C1 protein inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA] |
CTD |
PMID:23275455 |
|
NCBI chr11:56,902,342...57,221,070
Ensembl chr11:56,902,213...57,221,070
|
|
G |
Grin3a |
glutamate receptor ionotropic, NMDA3A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GRIN3A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:49,661,611...49,846,023
Ensembl chr 4:49,661,611...49,845,744
|
|
G |
Gstm2 |
glutathione S-transferase, mu 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GSTM2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:107,889,018...107,893,736
Ensembl chr 3:107,889,018...107,893,769
|
|
G |
Gstm4 |
glutathione S-transferase, mu 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GSTM4 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 3:107,937,887...107,952,495
Ensembl chr 3:107,947,724...107,952,210
|
|
G |
Has2 |
hyaluronan synthase 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HAS2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr15:56,529,023...56,557,942
Ensembl chr15:56,529,023...56,557,935
|
|
G |
Hbb-bh1 |
hemoglobin Z, beta-like embryonic chain |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HBG1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:103,490,845...103,492,369
Ensembl chr 7:103,490,844...103,492,371
|
|
G |
Hdac3 |
histone deacetylase 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HDAC3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:38,070,024...38,088,073
Ensembl chr18:38,068,897...38,088,069
|
|
G |
Hdac5 |
histone deacetylase 5 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HDAC5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:102,085,244...102,120,968
Ensembl chr11:102,085,258...102,120,992
|
|
G |
Hey2 |
hairy/enhancer-of-split related with YRPW motif 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HEY2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:30,708,355...30,718,779
Ensembl chr10:30,708,355...30,718,797
|
|
G |
Hlf |
hepatic leukemia factor |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HLF mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:90,227,361...90,281,745
Ensembl chr11:90,227,362...90,281,721
|
|
G |
Hmga1 |
high mobility group AT-hook 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMGA1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:27,774,798...27,782,649
Ensembl chr17:27,775,471...27,782,648
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMGCS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:120,151,887...120,169,796
Ensembl chr13:120,151,915...120,169,796
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMOX1 mRNA 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [ochratoxin A results in increased expression of HMOX1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMOX1 mRNA] |
CTD |
PMID:15179140 PMID:15994020 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hnf4g |
hepatocyte nuclear factor 4, gamma |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HNF4G mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:3,573,090...3,724,863
Ensembl chr 3:3,573,084...3,724,860
|
|
G |
Hoxb9 |
homeobox B9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HOXB9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:96,162,156...96,167,421
Ensembl chr11:96,162,283...96,167,421
|
|
G |
Hpca |
hippocalcin |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HPCA mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:129,005,363...129,019,712
Ensembl chr 4:129,005,363...129,015,829
|
|
G |
Hs3st1 |
heparan sulfate (glucosamine) 3-O-sulfotransferase 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HS3ST1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:39,771,278...39,802,791
Ensembl chr 5:39,771,278...39,912,818
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
multiple interactions |
ISO |
4'-cyanobiphenyl-4-sulfonic acid (6-aminopyridin-2-yl)amide inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of and results in increased activity of HSD11B1 protein; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of HSD11B1 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA; Hydrocortisone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA] |
CTD |
PMID:23275455 |
|
NCBI chr 1:192,903,917...192,946,345
Ensembl chr 1:192,903,942...192,946,383
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
decreases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSD11B2 mRNA [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B2 protein |
CTD |
PMID:22079614 PMID:23275455 |
|
NCBI chr 8:106,245,378...106,250,620
Ensembl chr 8:106,245,387...106,250,620
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
multiple interactions increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate promotes the reaction [bisphenol A results in decreased expression of HSD17B1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B1 mRNA |
CTD |
PMID:18815356 PMID:21273127 |
|
NCBI chr11:100,968,792...100,972,014
Ensembl chr11:100,969,237...100,971,353
|
|
G |
Hsd17b14 |
hydroxysteroid (17-beta) dehydrogenase 14 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSD17B14 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:45,204,345...45,216,745
Ensembl chr 7:45,204,317...45,217,176
|
|
G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
multiple interactions increases expression |
ISO EXP |
bisphenol A inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B2 mRNA] [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] affects the expression of HSD17B2 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B2 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B2 protein |
CTD |
PMID:18815356 PMID:21273127 PMID:21610156 |
|
NCBI chr 8:118,427,752...118,485,767
Ensembl chr 8:118,428,643...118,485,766
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:64,206,088...64,237,076
Ensembl chr13:64,206,080...64,237,044
|
|
G |
Hsd17b4 |
hydroxysteroid (17-beta) dehydrogenase 4 |
multiple interactions |
ISO |
[4-nitro-3-cresol co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD17B4 protein |
CTD |
PMID:18336853 |
|
NCBI chr18:50,261,268...50,329,337
Ensembl chr18:50,261,268...50,329,336
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:169,777,109...169,796,757
Ensembl chr 1:169,777,104...169,796,810
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
decreases expression increases expression multiple interactions |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSD3B1 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 protein 2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]]; Triiodothyronine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA] |
CTD |
PMID:18815356 PMID:21726595 PMID:22079614 |
|
NCBI chr 3:98,749,672...98,767,110
Ensembl chr 3:98,759,510...98,767,110
|
|
G |
Hsp90aa1 |
heat shock protein 90, alpha (cytosolic), class A member 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSP90AA1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:110,657,470...110,662,829
Ensembl chr12:110,657,039...110,669,162
|
|
G |
Hspa1a |
heat shock protein 1A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSPA1A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132
|
|
G |
Hspa5 |
heat shock protein 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSPA5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Hspa8 |
heat shock protein 8 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSPA8 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383
|
|
G |
Hsph1 |
heat shock 105kDa/110kDa protein 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSPH1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:149,540,308...149,562,594
Ensembl chr 5:149,537,752...149,559,841
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Reactive Oxygen Species results in increased expression of ICAM1 mRNA]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] |
CTD |
PMID:10495789 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Icam2 |
intercellular adhesion molecule 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ICAM2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:106,268,482...106,278,948
Ensembl chr11:106,268,482...106,278,901
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ID1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:152,578,171...152,579,330
Ensembl chr 2:152,578,171...152,579,330
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IDI1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:8,935,642...8,942,432
Ensembl chr13:8,935,537...8,942,487
|
|
G |
Ier3 |
immediate early response 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IER3 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr17:36,132,605...36,133,803
Ensembl chr17:36,132,576...36,133,815
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGF1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904
|
|
G |
Igf2bp2 |
insulin-like growth factor 2 mRNA binding protein 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGF2BP2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:21,877,759...21,982,049
Ensembl chr16:21,877,759...21,982,049
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions increases expression decreases expression increases secretion |
ISO |
1-Butanol inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]; 4'-cyanobiphenyl-4-sulfonic acid (6-aminopyridin-2-yl)amide inhibits the reaction [Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]]; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein; Dexamethasone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein]; Hydrocortisone promotes the reaction [Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]]; PLD1 protein affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]; Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 protein 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of IGFBP1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of IGFBP1 protein 8-Bromo Cyclic Adenosine Monophosphate results in increased secretion of IGFBP1 protein |
CTD |
PMID:16709600 PMID:17065600 PMID:18815356 PMID:20147733 PMID:21273127 PMID:21903722 PMID:23275455 More...
|
|
NCBI chr11:7,147,787...7,152,546
Ensembl chr11:7,147,782...7,152,546
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP5 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr 1:72,897,224...72,914,024
Ensembl chr 1:72,897,091...72,914,043
|
|
G |
Ikzf1 |
IKAROS family zinc finger 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of IKZF1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:11,634,970...11,722,930
Ensembl chr11:11,634,980...11,722,926
|
|
G |
Il18 |
interleukin 18 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL18 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein]] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL1A mRNA |
CTD |
PMID:11230753 PMID:22079614 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate promotes the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:11112151 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il27ra |
interleukin 27 receptor, alpha |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL27RA mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:84,756,915...84,769,250
Ensembl chr 8:84,756,923...84,769,218
|
|
G |
Il4 |
interleukin 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il4ra |
interleukin 4 receptor, alpha |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL4R mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 7:125,151,443...125,178,646
Ensembl chr 7:125,151,292...125,178,646
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of IL6 mRNA 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:16997883 PMID:21803157 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL7R mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:9,505,880...9,530,270
Ensembl chr15:9,505,874...9,530,262
|
| |